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ABSTRACT
The endocannabinoid (EC) system is a regulatory signaling system that is linked to a wide
spectrum of physiological and pathophysiological states, such as the modulation of neural
development, immune functions, metabolism, food intake, pain perception, cognition,
emotion/motivation, psychomotor control, and synaptic plasticity. Such a diverse signaling
system has raised high expectations as a target for drug development strategies for the
treatment of a wide variety of ailments. In addition EC signaling is linked to several
neuropsychiatric disorders that include drug addictions and neurodegenerative diseases.
During the last thirty years of research and discovery, many components of the EC system
are now well known, yet a complete understanding of this signaling system is lacking. To
reveal these remaining scientific mysteries, highly sophisticated analytical techniques are
required, in concert with pharmacological and biological strategies.
In this study, we identified significant variations in EC levels in specific regions of post-
mortem alcoholics’ brains, which also correlated with other neurotransmitter systems from
the  same  set  of  samples.  Further,  we  were  the  first  laboratory  to  identify  the  two  main
endocannabinoids; i.e., N-arachidonoyl ethanolamine and 2-arachidonoylglycerol, in
Caenorhabditis elegans (C. elegans), a free living soil nematode that is widely used as a model
organism in biological research. We also demonstrated significant changes in the EC levels
and global metabolome of these animals after food deprivation and alcohol administration.
These findings were based on novel mass spectrometric methods that were developed and
validated in our laboratory. We used liquid-liquid extraction to quench the metabolic
processes and extract analytes of interest from the biological samples.  Linear ion trap and
quadrupole time-of-flight detectors were used for qualitative analysis and metabolomics,
respectively. The quantitative analysis of ECs was made with a triple quadrupole instrument.
Positive electrospray ionization was used in the analysis of ECs. To investigate the
metabolomics,  we  expanded  the  coverage  of  metabolites  in  these  samples  by  using  two
different liquid chromatographic techniques (i.e., reversed phase and hydrophilic interaction
chromatography), in concert with both polarities in electrospray ionization.
The results demonstrate mass spectrometry to be a powerful analytical tool for unravelling
the secrets of EC system. Furthermore, C. elegans offers a unique, non-CB1R/CB2R-mediated
model for the study of EC signaling in vivo. This model will help further our understanding
of other physiological roles within the EC system (e.g., distinct physiological roles of N-
arachidonoylethanolamine and 2-arachidonoylglycerol).
National Library of Medicine Classification: QU 25, QU 85, QU 85.6, QU 120, QV 25, QV 126
Medical Subject Headings: Chemistry Techniques, Analytical; Chromatography, Liquid; Mass Spectrometry;
Spectrometry, Mass, Electrospray Ionization; Metabolism; Metabolomics; Metabolome; Lipids;
Endocannabinoids/analysis; Arachidonic Acids/analysis; Food Deprivation; Ethanol; Brain; Nematoda;
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TIIVISTELMÄ
Endokannabinoidijärjestelmä on välittäjäainejärjestelmä, joka on osallisena moneen
fysiologiseen ja patofysiologiseen tilaan. Näitä ovat mm. hermosolujen kehittymisen ohjaus,
vastustuskyky, metabolia, ruuan saanti, kivun aistiminen, kognitio, emootio/motivaatio,
psykomotorinen konrolli ja synaptinen plastisuus. Monipuolisuutensa ja keskeisten
vaikutustensa takia tätä järjestelmää on pidetty erittäin houkuttelevana kohteena
lääkekehitykselle. Edellämainittujen lisäksi endokannabinoidien signalointi on liitetty
useisiin neuropsykiatrisiin häiriöihin, joihin lukeutuu lääkeriippuvuus ja hermostoperäiset
sairaudet. Viimeisten kolmenkymmenen vuoden aikaiset tutkimukset ja löydökset ovat
luoneet kattavan kuvan EC-järjestelmästä, mutta kyseistä järjestelmää ja sen
toimintamekanismeja ei vieläkään tunneta täydellisesti. Näiden jäljellä olevien tieteellisten
arvoitusten ratkaisuun tarvitaan pitkälle kehittyneitä analyyttisiä tekniikoita, ja niiden
yhdistämistä farmakologisiin ja biologisiin menetelmiin.
 Tässä väitöskirjatutkimuksessa määritimme tilastollisesti merkittäviä eroja
endokannabinoidipitoisuuksissa alkoholistien tietyillä aivoalueilla. Me myös tunnistimme
ensimmäisenä maailmassa sukkulamadoista (C. elegans) kaksi pääendokannabinoidia, jotka
ovat 2-arakidonyyliglyseroli (2-AG) ja anandamidi (AEA). Sukkulamatoja käytetään laajasti
mallieliöinä biologisessa tutkimuksessa. Todistimme myös tilastollisesti merkittävät erot
endokannabinoidipitoisuuksissa sekä kokonaisaineenvaihdunnassa näissä madoissa ruuan
puutteen ja etanolialtistuksen vaikutuksesta. Edellämainitut löydökset perustuvat uusiin
massaspektrometrisiin menetelmiin, jotka kehitettiin ja validoitiin laboratoriossamme.
Käytössämme oli neste-nesteuutto näytteen entsyymitoiminnan lopettamiseen ja analyyttien
eristämiseen näytteestä. Lineaarinen ioniloukku ja korkean erotuskyvyn kvadrupoli-
lentoaika-analysaattori toimivat mittauslaitteistoina kvalitatiivisissa analyseissä ja
metabolomiikassa. Kvantitatiiviset mittaukset tehtiin kolmoiskvadrupolilaitteistolla.
Positiivinen sähkösumutusionisaatio oli käytössä endokannabinoideja määritettäessä.
Metabolomiikassa tutkittavien molekyylien määrää kasvatettiin käyttämällä kahta eri
kromatografista tekniikkaa, jotka olivat käänteisfaasitekniikka ja hydrofiilinen interaktio
kromatografia. Lisäksi metabolomiikassa käytettiin sekä positiivista että negatiivista
polariteettia sähkösumutusionisaatiossa.
Tuloksemme osoittavat massaspektrometrian erinomaiseksi analyyttiseksi työkaluksi
tutkittaessa ja ratkaistaessa puuttuvia palasia endokannabinoidijärjestelmästä. Lisäksi
sukkulamadot tarjoavat ainutkertaisen mallin tämän välittäjäainejärjestelmän tutkimiseen in
vivo. Tämä eläinmalli auttaa meitä osaltaan ymmärtämään paremmin tämän järjestelmän
merkitystä fysiologiaan, kuten 2-AG ja AEA erilaisia rooleja elimistössä.
Luokitus: QU 25, QU 85, QU 85.6, QU 120, QV 25, QV 126
Yleinen suomalainen asiasanasto: analyyttinen kemia; kemiallinen analyysi; kvalitatiivinen analyysi;
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massaspektrometria; lipidit; endokannabinoidit; sukkulamadot; koe-eläinmallit
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11 Introduction
Lipids  are  a  diverse  group  of  biochemicals  and  they  are  defined  as  hydrophobic  or
amphiphilic small molecules. The number of different lipid structures is estimated to vary
from 9,000 to 100,000 (Shevchenko and Simons, 2010). Lipids can be divided into eight
different categories of fatty acids (FA), glycerolipids (GL), glycerophospholipids (GP),
sphingolipids (SP), sterol lipids (ST), prenol lipids (PR), saccharolipids (SL), and polyketides
(PK) (Fahy et al., 2005). Lipids have many roles in cells as membrane constituents, for energy
storage, and signaling molecules. As membrane constituents they participate in membrane
trafficking, regulating membrane bound proteins, and creating lipid rafts that contribute to
various cellular functions. Lipids also have other functions as vitamins (A, D, E and K), acyl
carnitines, cardiolipins, and steroid hormones. Glycerophospholipids are not only a primary
component of cellular membranes, being part of the lipid bilayer, but they are also precursors
of lipid signaling molecules. Triglycerides have an important role in energy storage. Sterols,
such as cholesterol, are other important components of membrane lipids that are vital for
membrane fluidity. Steroids have roles as hormones and signaling molecules. Prenols, such
as carotenoids, serve as antioxidants and as precursors of vitamin A. In addition, vitamins E
and K as well as the ubiquinones are prenol derivatives. Therefore lipids have many crucial
roles in physiology and pathophysiology.
The present work concentrates on the endogenous cannabinoid system, which comprises
of two known cannabinoid receptors (CB1R and CB2R), their ligands, and enzymes that are
involved in the biosynthesis and inactivation of these ligands, as well as other factors that
regulate their action or transport (Ueda et al., 2013). Ligands to the cannabinoid receptors can
be botanical, endogenous or synthetic cannabinoids. The endocannabinoid (EC) system is a
regulatory system involved in physiological homeostasis, which is now known to modulate
neural development, immune function, metabolism, food intake, pain perception, cognition,
emotion/motivation, psychomotor control and synaptic plasticity (Fride, 2002). EC signaling
is further linked to the etiology of drug addiction (Serrano and Parsons, 2011) and several
neurodegenerative diseases (Maccarrone et al., 2011). Therefore this diverse signaling system
has raised expectations as a target for the development of new therapeutic drugs for a wide
variety of pathological conditions. Although many components related to EC system are
known, a complete understanding of this signaling system and its functions is not yet
available. To reveal these scientific mysteries, highly sophisticated analytical techniques like
mass spectrometry are needed in concert with pharmacological and genetic strategies, which
benefit from the use of animal models like the nematodes. Several mass spectrometric
methods  have  been  published  for  the  analysis  of  ECs  and  their  metabolism  in  biological
samples (reviewed in Kingsley and Marnett, 2009; Zoerner et al., 2011). However, this thesis
work concentrated on the development of new methods to analyze ECs in studies with
nematodes as model organisms for this research. Mass spectrometry has also been used in
the analysis of proteins related to the EC system (West et al., 2012), but these molecules and
techniques are outside the scope of the present work.
Mass  spectrometry  (MS)  is  based  on  the  production  of  ions,  which  are  subsequently
separated according to the mass-to-charge (m/z)  ratio  and finally  detected.  MS provides  a
wide dynamic range, reproducible quantitative analysis, high selectivity and sensitivity, plus
the ability to give specific information of molecular structure. As a detection method MS
allows us to analyze ECs in biological samples with extreme molecular complexity when
combined  with  gas  chromatography  (GC)  or  liquid  chromatography  (LC).  Recent
developments in mass spectrometric techniques and software solutions for handling the
2enormous amounts of data generated by these highly sophisticated techniques, have opened
the opportunity to study the non-targeted profiling of metabolites that include lipids. Using
non-targeted metabolite profiling, in concert with the targeted quantitative analysis of ECs,
it is possible to study EC metabolism, to obtain new information related to the complex lipid
interactions in the cells, and to gain a wider view of the EC system and its function in both
physiology and pathophysiology. Therefore MS has a central role in revealing the occurrence
of ECs in health and disease, in addition to providing useful information for pharmacological
or dietary interventions.
In this dissertation, Chapter 2 reviews the EC system and the mass spectrometric tools that
were  used to  unravel  the  mysteries  of  this  signaling system.  This  review chapter  contains
sections on the ECs main issues, such as:  the highly complex pathways related to the ECs
metabolism; the common history of the EC system and mass spectrometry; and the use of
mass spectrometry in the analysis of ECs and other molecules related to their metabolism.
This chapter also includes a description of the sample preparation aspect, in respect to
chromatographic techniques and mass spectrometry. The aims of the study are presented in
Chapter 3 and the methodological details in Chapter 4. The results are presented in Chapter
5 in three sections. The first section discusses the qualitative analysis of ECs, the second has
the quantitative analysis of ECs, and the last section presents the power of non-targeted
metabolite profiling in studying cell level changes after food deprivation and ethanol
administration in nematodes. These results are summarized and concluded in Chapter 6.
32 Review of the Literature
2.1 ENDOCANNABINOID SYSTEM
The EC system includes: two cannabinoid receptors (CB1R and CB2R) and their endogenous
ligands (endocannabinoids, ECs); enzymes that are involved in the biosynthesis and
inactivation of ECs; and other factors regulating ECs action or transport (Ueda et al., 2013).
The EC system has been linked to a wide spectrum of physiological and pathophysiological
functions that include food intake, pain perception, cognition, emotion/motivation,
psychomotor control, and neuroprotection (Fride, 2002; Mechoulam, 2002; reviewed in Di
Marzo, 2008). Recent studies have implicated the EC system in several neurodegenerative
diseases and neuropsychiatric disorders, as well as in the reinforcing, dependency and
addictive effects of ethanol and some other drugs of use, misuse and abuse (Basavarajappa,
2007; Maldonado et al., 2006; Vinod and Hungund, 2005; Serrano and Parsons, 2011;
Maccarrone  et  al.,  2011).  The  EC  system  is  considered  to  be  a  promising  target  for  drug
development, in the form of receptor agonists and antagonists, as well as compounds
effecting enzymes related to the hydrolysis of ECs (reviewed in Di Marzo, 2008).
2.1.1 Endocannabinoid signaling
Cannabinoid receptors are seven-transmembrane-domain proteins coupled to G-proteins.
CB1R is the most abundant G-protein-coupled receptor in the mammalian brain (Herkenham
et al., 1991; Glass et al., 1997; Egertová et al., 2003). The distribution of CB1R is primarily in
the central nervous system (CNS), and it  is highly heterogeneous. The expression of CB1R
was found to be very high in the basal ganglia, cerebellum, hippocampus, and parts of the
olfactory cortex. The expression was moderate to high in the cerebral cortex, olfactory bulb,
amygdala, and brainstem nuclei (Herkenham et al. 1991; Tsou et al. 1997; reviewed in Freund
et al. 2003). CB1R has also been found in peripheral tissues, such as the gastrointestinal tract,
the cardiovascular and reproductive systems (Croci et al., 1998, Pertwee, 1997, Pertwee, 2001:
Wagner et al., 2001). CB1Rs are most frequently localized in presynaptic neurons, but they
can also be found in postsynaptic neurons (Kano et al., 2009). In contrast, CB2Rs are mainly
located  peripherally,  and  are  generally  associated  with  the  immune  system  (for  review
Howlett et al., 2002). CB2R has been also detected in the CNS (Ashton et al., 2007; Gong et
al.,  2006; Van Sickle et al.,  2005; for a review on structure, function and distribution of CB
receptors see Kano et al., 2009; Svízenská et al., 2008; Rodríguez de Fonseca et al., 2005; Pazos
et al., 2005; Harkany et al., 2007).
ECs are produced and released ´on demand´ from postsynaptic neurons upon
depolarization (Robbe et al., 2002; Melis et al., 2004; Riegel and Lupica, 2004). 2-arachidonoyl
glycerol (2-AG) and N-arachidonoyl ethanolamine (anandamide, AEA) are considered to be
the main endogenous molecules responsible for endocannabinoid signaling. ECs play a role
as retrograde messengers and they mediate short- and long-term forms of plasticity at both
excitatory and inhibitory synapses (Wilson and Nicoll, 2001; Kreitzer et al., 2001; Ohno-
Shosaku et al., 2001; Jung et al., 2005; Robbe et al., 2002; Gerdeman et al., 2002). ECs mediated
short-term synaptic plasticity includes depolarization-induced suppression of inhibition
(DSI) and excitation (DSE) (Wilson and Nicoll, 2001; Kreitzer et al., 2001; Ohno-Shosaku et
al., 2001). DSI and DSE are formed when ECs suppress the release of presynaptic ·-
aminobutyric acid (GABA) and glutamate, respectively. In addition, EC signaling mediates
prolonged weakening of synaptic strength and a long-lasting increase in the strength of
synaptic signaling, these effects are termed long-term depression (LTD) and long-term
4potentiation (LTP) of synaptic transmission, respectively (Robbe et al., 2002; Gerdeman et al.,
2002). Postsynaptic formation of 2-AG has been reported to be a major signaling molecule for
short- and long-term synaptic plasticity (Gerdeman et al., 2002; Chevaleyre and Castillo,
2003; Jung et al., 2005; Lafourcade et al., 2007; Uchigashima et al., 2007; Schlosburg et al., 2010;
reviewed  in  Kano  et  al.,  2009;  Ohno-Shosaku  and  Kano,  2014).  AEA  may  also  mediate
retrograde signaling via EC receptors, but it has also been implicated in tonic EC signaling,
therefore performing a role that is distinct from 2-AG (Grueter et al., 2010; Kim and Alger,
2010; reviewed in Ohno-Shosaku and Kano, 2014). In addition, AEA may participate in
synaptic plasticity with the transient receptor potential vanilloid 1 (TRPV1) receptor
(Elphick, 2012). CB1R and CB2R also regulate cyclic adenosine monophosphate (cAMP)
production by inhibiting adenylyl cyclase, decreasing Ca2+ conductance,  increasing  K+
conductance, and increasing mitogen-activated protein kinase activity (Howlett et al., 1984;
Bayewitch et al., 1995; Bidaut-Russell et al., 1990; Mackie et al., 1993; Mackie and Hille, 1992;
Mackie et al., 1995; Bouaboula et al., 1995; Bouaboula et al., 1996). Activation of CB1R has
also been reported to stimulate phosphatidylinositol 3-kinase and protein kinase B (Gomez
del Pulgar et al., 2000; Molina-Holgado et al., 2002). Furthermore, ECs appear to act in a
nonretrograde manner and via astrocytic CB1R receptors (Castillo et al., 2012). In
nonretrograde  signaling,  ECs  modulate  neural  function  and  synaptic  transmission  by
activating postsynaptic CB1R or TRPV1. In gliotransmission, ECs indirectly modulate
presynaptic or postsynaptic functions (Castillo et al., 2012).
Besides  the  known  cannabinoid  receptors  CB1R  and  CB2R,  ECs  and  their  metabolic
products may also act as ligands for a variety of other non-cannabinoid receptors; e.g. GPR18
(McHugh et al., 2010), GPR55 (Ryberg et al., 2007; Lauckner et al., 2008; Baker et al., 2005;
Johns et al., 2007), GPR119 (Overton et al., 2006), TRPV1 ligand-gated channels (Zygmunt et
al., 1999; Smart et al., 2000; Suh et al., 2005; Szallasi et al., 2007), and the peroxisome
proliferator-activated receptors (PPAR) subtypes ΅ , Ά and · (Sun et al., 2007; O'Sullivan, 2007;
Fu et al., 2003; Bouaboula et al., 2005; LoVerme et al., 2005; Rockwell et al., 2006; reviewed in
O´Sullivan and Kendall, 2010). PPARs regulate cell differentiation, insulin sensitivity,
glucose  homeostasis,  and  lipid  metabolism  (reviewed  in  O'Sullivan,  2007).  ECs  may  also
activate retinoid X receptors (RXRs) that heterodimerize with PPARs (Sun and Bennet, 2007).
Further, at pharmacologically relevant concentrations, ECs can modulate the functional
properties of voltage-gated (Ca2+, Na+ and  some  of  K+ channels) and ligand-gated (i.e.,
serotonin type 3, nicotinic acetylcholine and glycine receptors) ion channels (Mackie and
Hille, 1992; Mackie et al., 1995; McAllister et al., 1999; reviewed in Oz, 2006).
2.1.2 Endocannabinoids and endogenous cannabimimetics
The structure of ̇9-tetrahydrocannabinol (THC), the main psychoactive compound in drug
cannabis, was reported in 1964 (Gaoni and Mechoulam, 1964). The identification of the
structure was based on, at that time novel, nuclear magnetic resonance spectroscopy (NMR).
Since  then,  it  was  long  believed  that  THC  does  not  have  any  specific  binding  site(s)  or
endogenous mediators  in  the  CNS (see  review Mechoulam and Hanus,  2000).  By the  mid
1980´s, however, cannabinoid action was found to be highly stereospecific, which suggested
the presence of a specific binding site for cannabinoids in the CNS (Mechoulam et al., 1988).
The discovery of CB1R, the main binding site for THC, was published by Devane and co-
workers in 1988, which further suggested the existence of endogenous cannabinoids. The
other cannabinoid receptor (CB2R) was eventually identified and cloned in 1992 (Munro et
al., 1993). ECs are defined as endogenous compounds that are able to bind and activate the
cannabinoid receptors (Di Marzo and Fontana, 1995). Cannabimimetic or ´endocannabinoid-
like´ molecules show either a modest affinity or lack activity at the CB1R and CB2R receptors,
yet they do potentiate the effect of ECs (Ben-Shabat et al., 1998). Such enhancements of EC
activity  by  congeners  that  apparently  lack  a  specific  binding  affinity  for  the  known
cannabinoid receptor have been described as an entourage effect (Mechoulam et al., 1998).
5Such interactions between the multiple cannabimimetics are highly complex, both at the level
of signal transduction and metabolism. Examples of molecular structures of these
compounds are presented in Figure 1.
AEA, an N-acylethanolamine  (NAE)  derivative  of  arachidonic  acid,  was  the  first  EC
discovered to have high affinity for the CB1R receptor, in that case acting as an endogenous
lipid agonist (Devane et al., 1992). One year later, two other NAEs were discovered to bind
and activate CB1R (Hanus et al., 1993). Like AEA, the identification of homo-·-linolenoyl
ethanolamine (LEA) and docosatetraenoyl ethanolamine (DHEA) were made with mass
spectrometry (Hanus et al., 1993). AEA behaves as a partial agonist for both CB1R and CB2R
receptors (Sugiura et al., 2002). Concentrations in the brain tissue for AEA range from 10 to
100 pmol/g (wet weight) (Stella et al., 1997). Other NAE lower affinity CB1R agonists are
LEA, DHEA, docosatetraenoyl- (DEA), eicosatrienoyl-, and eicosapentaenoyl ethanolamine
(EPEA). In addition to CB1R and CB2R, DHEA and EPEA are reported to activate PPAR-·
(Brown et al., 2013; Rovito et al., 2013). Oleoyl ethanolamine (OEA), palmitoyl ethanolamine
(PEA) and stearoyl ethanolamine (SEA) are cannabinoid receptor-inactive cannabimimetic
compounds.  OEA is  known for  its  appetite-suppressing effect  and as  an inhibitor  of  AEA
uptake and degradation (Fu et al., 2003; Rakhshan et al., 2000). Whereas PEA is known to be
anti-inflammatory, neuroprotective and an anti-nociceptive agent in mammals (Calignano et
al.,  2001).  Both  OEA  and  PEA  are  hypothesized  to  increase  AEA  levels  in  tissues  by
competition for fatty acid amide hydrolase (FAAH)-mediated hydrolysis, thus resulting in a
net potentiation of AEAs actions on cannabinoid or/and vanilloid receptors in this way
(Mechoulam et al., 1998; Smart et al., 2000; Ho et al., 2008). PEA functions as an agonist of
PPAR-΅ (LoVerme et al.,  2005).  OEA is reported to be an agonist of PPAR-΅,  TRPV-1 and
GPR119 (Pavón et al., 2010). O-Arachidonoyl ethanolamine (virodhamine) has been found to
be a partial agonist of CB1R and a full agonist of CB2R (Porter et al., 2002).
In 1995, the monoacyl glyceride (MAG) of arachidonic acid, 2-arachidonoyl glycerol (2-
AG), was subsequently identified as an agonist of CB1R and CB2R (Mechoulam et al., 1995;
Sugiura et al., 1995). As in the case of NAEs, NMR and GC-MS instrumentation were used
for the identification of 2-AG. This molecule acts as a full agonist for CB1R and CB2R (Sugiura
et al., 2006). It is present at 100 to 1,000 higher concentrations than AEA in the brain (Sugiura
et al., 1995; Stella et al., 1997). 2-AG and AEA have differing concentrations in different
regions of the brain (Felder et al., 1996; Bisogno et al., 1999). Interestingly, it has been noticed
that  2-AG levels  are  more  stable  than AEA level  in  rat  brain,  which have greater  regional
variance (Buczynski and Parsons, 2010). Another MAG, 2-oleoylglycerol (2-OG) activates
GPR119 and stimulates the release of glucagon-like peptide-1 (Hansen et al., 2011). Hanus
and co-workers (2001) identified 2-arachidonyl glycerol ether (2-AGE, noladin ether) with
NMR and GC-MS and found that it binds to CB1R. Subsequently, 2-AGE was reported to act
as a full agonist of human CB1R and CB2R (Steffens et al., 2005; Shoemaker et al., 2005).
Like AEA, N-arachidonoyl dopamine (NADA) activates CB1R with affinity in the nano-
molar range (Bisogno et al., 2000), and it is more potent than AEA at TRPV1 (Bisogno et al.,
2000; Bezuglov et al., 2001; Huang et al., 2002). From other identified acyl-dopamines, N-
oleoyl-dopamine (OLDA) shows a  modest  affinity  for  the  CB1R and N-palmitoyl- and N-
stearoyl-dopamine are inactive at CB1R and have very low TRPV1 activity (Chu et al., 2003).
OLDA has also been reported to activate GPR119 (Chu et al., 2010). The sleep-inducing
substance, oleamide (ODA) is a full agonist at the CB1R and otherwise has similar
characteristics as AEA (Leggett et al., 2004). In addition, fatty acids conjugated to amino acids
have been found to participate in the EC system of mammalian tissues, at least as part of the
entourage  effect.  Examples  of  such  lipoamino  acids  are  pain  inhibiting N-
arachidonoylglycine (NArGly), N-arachidonyl-·-aminobutyric acid (NAGABA), N-
arachidonylalanine (NAAla), and N-arachidonoylserine (NArS) for which vasodilatory
properties have been described (Huang et al., 2001; Milman et al., 2006).
6In  addition  to  lipophilic  compounds,  hemopressin  (Hp)  has  been  reported  to  act  as  an
inverse agonist at CB1R (Heimann et al., 2007). N-Terminally extended forms of Hp act as
CB1R agonists (Gomes et al., 2009). These include either three (RVD-HP΅) or two (VD-Hp΅)
additional amino acids, as well as a Ά-hemoglobin-derived peptide with a sequence similarity
to hemopressin (VD-HpΆ).
Figure 1. The molecular structures of various botanically and endogenously produced
cannabinoids. The main psychoactive compound in drug cannabis is Ʃ9-tetrahydrocannabinol
(THC) (I). The endocannabinoids (ECs) have a fatty acyl group linked to an ethanolamine (in N-
or O-acylethanolamines, NAEs and OAEs, respectively), glycerol (in monoacylglycerols, MAGs),
dopamine (in N-acyldopamines), or an amino acid. The following ECs and cannabimimetic
compounds are presented as THC (I), 2-AG (II), 2-AGE (III), NADA (IV), virodhamide (V), AEA
(VI), LEA (VII), EPEA (VIII), DHEA (IX), OEA (X), PEA (XI), ODA (XII), NArGly (XIII), and NArS
(XIV).
2.1.3 Metabolism of endocannabinoids
ECs are partitioned into membranes according to a thermodynamically favorable orientation
and location. The alignment of AEA has been shown to be parallel  to the lipid acyl chains
(Lynch  and  Reggio,  2005;  Tian  et  al.,  2005).  Enzymes  related  to  the  biosynthesis  and
degradation of ECs are membrane-bound (Cadas et al., 1997; Jin et al., 2007; Childers and
Breivogel, 1998; reviewed in Placzek et al., 2008; Wang and Ueda, 2009). The lipid rafts play
a crucial role in ECs uptake and signaling through the cannabinoid receptors (McFarland et
al., 2004; Barnett-Norris et al., 2005; Rimmermann et al., 2008). Complementary localization
of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) in the CNS, pre-
synaptic and post-synaptic, respectively, has been reported and suggests different roles for
7AEA and 2-AG in the brain (Gulyas et al., 2004). Despite their similarity in chemical structure,
the biosynthetic pathways of the two main ECs; AEA and 2-AG, are completely different.
AEA and other NAEs are principally biosynthesized from glycerophospholipids via N-
acylated ethanolamine phospholipid (NAPE) by a combination of Ca2+-dependent N-
acyltransferase (Ca-NAT) and N-acyl-phosphatidylethanolamine-hydrolyzing
phospholipase D (NAPE-PLD) (Schmid, 2000). This two-step metabolic process is known as
the transacylation-phosphodiesterase pathway (Figure 2). N-Acylation of
phosphatidylethanolamine  (PE)  is  the  first  step  in  this  pathway,  where  an  acyl  group  is
transferred from the sn-1 position of a glycerophospolipid to the amino group of PE to form
NAPE. In this context, NAPE is used as a generic term for all three possible species; i.e. the
diacyl (N-acyl-phosphatidylethanolamine (NAPE)), the alkenylacyl (plasmalogen-type, N-
acyl-plasmenylethanolamine (pNAPE)), and the alkylacyl (N-acyl-plasmanylethanolamine)
derivatives (Astarita et al., 2008; Tsuboi et al., 2013; Ueda et al., 2013). In addition to serving
as  precursors  for  NAEs,  NAPE  has  been  shown  to  participate  in  membrane  stabilization
(Coulon et al., 2012). Metabolically, NAPE is catalyzed by Ca-NAT, and the activation of NAT
is triggered by an increase in intracellular Ca2+ concentration (Jin et al., 2007). NAT can use
different glycerophospholipids as acyl donors, such as phosphatidylcholine (PC), lyso-PC,
PE, and cardiolipin (Schmid et al., 1990; Sugiura et al., 1996; Cadas et al., 1997). Since the acyl
group is specifically taken from the sn-1 position of the donor phospholipid, and because this
position is primarily occupied by saturated and monounsaturated fatty acids, the majority of
N-acyl  groups  in  NAEs  are  more  likely  to  have  these  types  of  fatty  acids.  Therefore,  the
amount of polyunsaturated N-acyl derivatives of NAEs, such as AEA, is relatively minor in
mammalian tissues. Enzymatic NAT activity is highest in the brain (Cadas et al., 1997), and
is important in the developmental phase (Moesgaard et al., 2000). In addition, NAPE can be
formed by two other proteins belonging to the lecithin retinol acyltransferase (LRAT) family;
i.e., Ca2+-independent NAT (iNAT) and HRAS-like suppressors (HRASLS1-5) (Jin et al., 2007;
Uyama et al., 2009; Uyama et al., 2012; Ueda et al., 2013). The second reaction of the
transacylation-phosphodiesterase pathway is the hydrolysis of NAPE by NAPE-PLD to form
AEA, or other NAEs and phosphatidic acid (PA) (Okamoto et al., 2004). The highest NAPE-
PLD activities are found in brain, kidney, testis, heart, and lung (Okamoto et al., 2004; Schmid
et al., 1983; Liu et al., 2002). NAPE-PDL is expressed in specific populations of neurons, and
it  has  been  suggested  that  NAEs  act  as  anterograde  synaptic  signaling  molecules  that
regulate the activity of postsynaptic neurons (Egertová et al., 2008). Other pathways
converting NAPEs to NAEs have been reported (Leung et al., 2006). For example, AEA and
PEA  have  been  reported  to  form  by  sequential  actions  of  phospholipase  A2  and
lysophospholipase D (Sun et al., 2004). AEA biosynthesis through glycerophospho-N-acyl
ethanolamine, catalyzed by ΅ȦΆ-hydrolase 4 (ABHD4) and glycerophosphodiester
phosphodiesterase 1 (GDE1), has been also reported (Simon and Cravatt, 2006, 2008). In
addition, AEA may be biosynthesized from N-arachidonoyl-PE in a two-step process with a
phospholipase C (PLC) like hydrolysis of N-arachidonoyl-PE and subsequent
dephosphorylation of the resulting anandamide phosphate by protein tyrosine phosphatase
(PTPN22) (Liu et al., 2006; Liu et al., 2008). The formation of AEA by a condensation reaction
of free arachidonic acid and ethanolamine has also been reported (Arreaza et al., 1997;
Kurahashi et al., 1997).
8Figure 2. The biosynthesis of AEA by the transacylation-phosphodiesterase pathway. Other
pathways  of  NAEs  formation  are  described  herein,  and  in  a  review by  Ueda  et  al.,  2013.  The
moieties of arachidonoyl and ethanolamine are highlighted in blue and red, respectively.
Abbrevations: AEA, anandamide; Lyso-PC, lysophosphatidylcholine; NAPE, N-acyl-
phosphatidylethanolamine; PA, phosphatidic acid; PE, phosphatidylethanolamine; and PC,
phosphatidylcholine.
The major pathway for the biosynthesis of 2-AG utilizes diacylglycerols (DAGs), which are
produced from the hydrolysis of 2-arachidonoyl-phosphatidylinositol (PI) by PLC (Prescott
and Majerus, 1983; reviewed in Sugiura et al., 2006). The biosynthetic production of 2-AG is
presented in Figure 3. In mammalian tissues, 1-stearoyl-2-arachidonoyl-sn-glycerol is the
major molecular specie of DAGs derived from PIs, which allows for a higher production of
2-AG over monoacylglycerols (MAGs) (Prescott and Majerus, 1983). PIs also participate in
the production of 2-AG with lyso-PI-specific PLC through lyso-PI by phospholipase A1
(PLA1) (Ueda et al., 2013). In addition, PIs can form phosphatidylinositol bisphosphate (PIP2),
which can be hydrolyzed to DAGs by PIP2-selective phospholipase C. The other sources for
2-arachidonoyl DAG are phosphatidic acids (PAs), lysophosphatidic acids (Lyso-PA), and
9phosphatidylcholines (PCs) (Nakane et al., 2002; reviewed in Sugiura et al., 2006; Ueda et al.,
2013). The formation of DAGs from PAs is catalyzed by a PA phosphohydrolase. The DAGs
are hydrolyzed by sn-1 selective DAGLs at the sn-1 glycyl position to yield MAGs, such as 2-
AG  and  a  free  fatty  acid  (Prescott  and  Majerus,  1983;  Bisogno  et  al.,  2003).  Two  DAGL
isozymes; DAGL΅ and DAGLΆ,  have been cloned and characterized (Bisogno et al.,  2003).
DAGL΅ has  been  reported  to  be  more  abundant  in  the  adult  brain  and  is  located  at  the
postsynaptic neurons that face CB1-expressing terminals (Bisogno et al., 2003; Yoshida et al.,
2006). Studies with DAGL΅-deficient mice provide strong evidence that DAGL΅ is involved
in  the  generation  of  2-AG  and  is  responsible  for  CB1R-dependent  retrograde  signaling
(Tanimura et al., 2010). Interestingly, DAGLΆ is more abundant in the developing brain, and
mostly located on axonal tracks (Bisogno et al., 2003).
Figure 3. The biosynthesis of 2-AG. Other pathways of 2-AG formation are described herein, and
in reviews by Sugiura et al., 2006 and Ueda et al., 2010. The moiety of arachidonoyl and glycerol
are  highlighted  in  blue  and  red.  Abbreviations:  2-AG,  2-arachidonoyl  glycerol;  DAG,
diacylglycerol; FA, fatty acid; and PI, phosphatidylinositol.
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The termination of EC signaling begins with the transport of these signaling molecules
across the plasma membrane and, for the most part,  enzymatic hydrolysis into a free fatty
acid, ethanolamine, and glycerol. Several different transport mechanisms have been
suggested including involvement of a specific transport protein, passive diffusion gated by
FAAH, intracellular sequestration, formation of endocannabinoid-cholesterol complexes,
and caveolae-dependent endocytosis (Deutsch et al., 2001, Kaczocha et al., 2006; Oddi et al.,
2008, Di Pasquale et al., 2009; reviewed in Fowler, 2013). More recently, fatty acid-binding
proteins have been reported to participate in the transport of NAEs to nuclear receptors
(Kaczocha et al., 2009; Kaczocha et al., 2012). The major degradation pathway of NAEs is by
enzymatic hydrolysis with FAAH, which occurs postsynaptically at intracellular membranes
(Schmid et al., 1985; Deutsch and Chin, 1993; Cravatt et al., 1996; Egertová et al., 1998;
Egertová et al., 2003; reviewed in Kano et al., 2009; Ueda et al., 2013). An isoform of FAAH,
known as FAAH-2 is reported to have variable distribution among placental mammals, and
appears in adiposomes (Wei et al., 2006; Kaczocha et al., 2010). Another fatty acid amidase,
N-acylethanolamine-hydrolyzing acid amidase (NAAA) has a higher enzymatic activity
towards PEA than AEA (Ueda et al., 2001). FAAH is also able to hydrolyze 2-AG (Cravatt et
al., 1996; McKinney and Cravatt, 2005). MAGLs degradate 2-AG presynaptically, in the
cytosol and intracellular membranes (Dinh et al., 2002; Gulyas et al., 2004). Less than 15 % of
2-AG  activity  is  hydrolyzed  by  other  enzymes;  such  as  ABHD6,  ABHD12  and  FAAH
(Blankman et al., 2007; Savinainen et al., 2012). Oxidative metabolism of ECs has also been
reported. For example, cyclo-oxygenase 2 (COX2) has been reported to transform AEA and
2-AG into prostaglandin ethanolamines (prostamides) and prostaglandin glycerol esters,
respectively (Yu et al., 1997; Woodward et al., 2001; Ross et al., 2002). In addition,
lipoxygenases (LOX) and cytochrome P450 oxidases (CYPs) have been shown to metabolize
ECs (Kozak and Marnett, 2002; Ueda et al., 2010; Rouzer and Marnett, 2011). Degradation
products of ECs are recycled into membrane phospholipids. Also, 2-AG can re-esterify with
phospholipids through phosphorylation or acylation of 2-AG hydroxyl groups (Sugiura et
al., 2002). The most common degradation pathways of AEA and 2-AG and some examples
of their oxidated metabolites, are presented in Figure 4.
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Figure 4. The degradation of  AEA and 2-AG. Abbrevations: 2-AG, 2-arachidonoyl  glycerol;  ABHD, Įǃ-hydrolase domain containing proteins; AEA,
anandamide; COX2, cyclo-oxygenase 2; CYP, cytochrome P450 oxidases; EET-EA, for example 14(15)-epoxyeicosatrienoyl ethanolamine; EET-G, for
example 2-(14,15-epoxyeicosatrienoyl) glycerol; FAAH, fatty acid amide hydrolase; HETE-EA, for example 20-hydroxyeicosatetraenoyl ethanolamine;
HETE-G, for example 20-hydroxyeicosatetraenoic acid glycerol ester; HPETE-EA, for example 12-hydroperoxyeicosa-5,8,10,14-tetraenoyl
ethanolamine; HPETE-G, for example 12-hydroperoxyeicosa-5,8,10,14-tetraenoic acid glycerol ester; LOX, lipoxygenases; MAGL, monoacylglycerol
lipase; NAAA, N-acylethanolamine-hydrolyzing acid amidase; PG-EA, prostaglanding F2Į ethanolamine; and PG-G, prostaglandin E2 glycerol ester.
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2.2 COMMON HISTORY OF THE ENDOCANNABINOID SYSTEM AND MASS
SPECTROMETRY
Di Marzo and Fontana proposed the term ”endocannabinoids” in 1995, for the endogenous
cannabinoids that activate the CB1R (Di Marzo and Fontana, 1995), and soon after that came
the term “endocannabinoid system”. According to the PubMed database (National Center
for  Biotechnology  Information,  U.S.  National  Library  of  Medicine,  MD,  USA)  15,197  and
6,497 scientific publications have been published from 1992 to 2014 when searching for
“cannabinoid” and “endocannabinoid”, respectively. The discovery and basic research
related to EC system coincide with developments in MS instrumentation (Table 1). According
to PubMed, the search term “Mass spectrometry” identifies 210,872 scientific publications
between 1992 and 2014. A search with the combined terms “cannabinoid AND mass
spectrometry” and “endocannabinoid AND mass spectrometry” identified 1,124 and 368
research  publications,  respectively,  during  the  same  time  period.  Figure  5  illustrates  the
number of publications per year related to the search terms “mass spectrometry” (Fig. 5 A)
and “mass spectrometry AND endocannabinoids” (Fig. 5 B).
Figure 5. The  number  of  publications  by  year,  from 1992  to  2014.  Search  terms  were  “Mass
spectrometry” (A) and “Endocannabinoid AND Mass spectrometry” (B). The scientific search was
abstracted in PubMed (National  Center for  Biotechnology Information,  U.S.  National  Library of
Medicine, MD, USA).
The  history  of  EC  research  is  linked  to  advances  in  mass  spectrometry  (Table  1).  The
“father”  of  mass  spectrometry,  Cavendish  Professor  at  Cambridge  University  (U.K.)  J.J.
Thomson, studied the transmission of electricity through gases and, more precisely, particle
theory of cathode rays that led to the discovery of electrons. For this work, Thomson received
the 1906 Nobel Prize in Physics (see The Official Web Site of the Nobel Prize, Nobelprize.org).
Research by others who would become Nobel laureates were also critical to these early days
of mass spectrometry; for example in 1911 Professor W. Wien was awarded the Nobel Prize
in  physics  for  his  discoveries  of  the  laws  governing  the  radiation  of  heat.  Professor  Wien
recognized  that  canal  rays  are  positively  charged  particles  and  that  these  rays  contained
hydrogen ions, later named the protons, then he made the first e/m measurement of a proton
(Moore  et  al.,  1985).  This  work  complimented  the  work  by  Eugen  Goldstein  and  Prof.  J.J.
Thomson and laid the foundation for mass spectrometry.
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One of the biggest discoveries in the early days was the existence of isotopes, and one of
the first applications of MS was related to exploring the fundamental nature of the atom.
Pioneering work by Professors F. McLafferty, K. Biemann, and C. Djerassi in the 1950s and
1960s triggered an understanding of molecular fragmentation within the instrument, and this
work laid the groundwork for mass spectrometry in modern biological research (Griffiths,
2008).
Since the first mass spectrometer, constructed by Professor J.J. Thomson in 1912, the
development of instrument techniques has dramatically expanded the usability of MS from
the measurements of electrons to large macromolecules in biological samples (Table 1). As
early as 1917, the first evidence of electron ionization and magnetic sector mass spectrometry
was introduced by Dr. A.J.  Dempster (Dempster,  1917).  This primitive instrument had the
same basic theory and design as mass spectrometers that are still used today. Subsequent
commercialization made MS instrumentation available to researchers. The first commercial
MS instrument appeared in 1940s. In 1968 and 1975 the first commercial quadrupole and GC-
MS  were  presented,  respectively,  and  finally  LC-MS  instruments  became  available  in  the
1990´s.
GC-MS had a vital role in the discovery and identification of ECs, that is, AEA, 2-AG, LEA,
DHEA and 2-AGE (Devane et al., 1992; Hanus et al., 1993; Mechoulam et al., 1995; Sugiura et
al., 1995; Hanus et al., 2001). Nowadays, LC-MS is the most common technique used for the
analysis of ECs and the study of their metabolism. The main challenge for coupling LC and
MS  detection  was  the  phase  transfer  from  liquid  to  gas,  which  is  currently  solved  by
atmospheric pressure ionization (API) techniques, that is, electrospray ionization (ESI) and
atmospheric pressure chemical ionization (APCI) (Kostiainen and Kauppila, 2009). ESI was
introduced for the analysis of small organic molecules in 1984 (Yamashita and Fenn, 1984).
There are existing techniques that are not yet widely utilized for the analysis of ECs and
their metabolism. From LC-MS ionization techniques, atmospheric pressure photoionization
(APPI) was introduced as new ionization method that widened the analysis towards less
polar compounds, which are difficult to analyze with other API sources (Robb et al., 2000).
So far, APPI has not been used for the analysis of ECs. In addition, Fourier transform-based
mass spectrometers (FTMS), that is, Fourier transform ion cyclotron resonance (FTICR)
(Comisarow and Marshall, 1974) and Orbitrap (Makarov, 2000), are not yet documented as
analyzers for ECs, which could be explained by the high cost of these instruments and the
current lack of need for the highest possible mass accuracy and resolution. In the 1990s, ESI
and matrix-assisted laser desorption/ionization (MALDI) enabled the use of MS detection
over a wide range of biological applications (Karas and Hillenkamp, 1988; Yamashita and
Fenn, 1984; Fenn et al., 1989; reviewed in Fenn 2002).  MALDI can also be used in imaging
mass spectrometry (IMS), which enables the visualization of spatial distribution for
biomolecules  (Goto-Inoue  et  al.,  2011).  MALDI-TOF  IMS  has  been  used  with  functional
autoradiography to study human post-mortem brain lipid distribution and the localization
of Lyso-PA and cannabinoid receptors (Veloso et al., 2011). Also in 2004, desorption
electrospray ionization (DESI) was introduced in combination with linear ion trap MS, and
has been also used to study changes in rat brain lipids that include NAPEs and NAEs during
neonatal brain ischemia (Takáts et al., 2004; Janfelt et al., 2012). Lipids are known to have
many  isomers  and  isobaric  compounds,  which  have  the  same  nominal  mass  but  differ  in
molecular structure. The identification power of ion mobility (IM) spectroscopy, with or
without its combination to MS, has been also tested to resolve these problems of structural
identification (Kliman et al., 2011).
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Table 1. A common history of the endocannabinoid system and mass spectrometry.
Year Discovery Reference
1852 Suggestion of hydrogen as cation in gas phase by Sir
William Robert Grove
Reviewed in Moore et al., 1985
1858 Discovery of cathode rays by Prof. Plücker; magnetic
and electrostatic means cause deflections to the
electrical discharges in rarefied gases
Reviewed in Moore et al., 1985
1886 Discovery of canal rays; opposite direction stream as
the electron flow in the cathode ray tube
Goldstein, 1886
1897 Discovery of electrons by Prof. Thomson Reviewed in Griffiths, 2008
1902 Discovery of proton by Prof. Wien Wien, 1902
1912 First Mass Spectrometer by Prof. Thomson Reviewed in Griffiths, 2008
1917 First “modern” MS and first electron impact source for
solids
Dempster, 1917
1921 Nobel Prize – Frederick Soddy for his investigations
into the origin and nature of isotopes
The Official Web Site of the Nobel Prize,
Nobelprize.org
1922 Nobel Prize – William Aston for his discovery of
isotopes in non-radioactive elements
The Official Web Site of the Nobel Prize,
Nobelprize.org
1929 First electron impact ionization source for gases Bleakney, 1929
1939 Nobel Prize – Ernest O. Lawrence for development of
the cyclotron
The Official Web Site of the Nobel Prize,
Nobelprize.org
1942 First commercial MS installation; Consolidated
Engineering Corporation – Atlantic Refining Company
Reviewed in Gohlke and McLafferty, 1993
1946 Time-of-flight (TOF) Stephens, 1946
1953 Quadrupole mass filter and Quadrupole ion trap Reviewed in Paul, 1990
1955 First mass analyzer (TOF) connection to GC Gohlke, 1959, Reviewed in Gohlke and
McLafferty, 1993
1959 McLafferty rearrangement theory McLafferty, 1959
1964 Structure of Ʃ9-tetrahydrocannabinol (THC) Gaoni and Mechoulam, 1964
1966 Chemical ionization (CI) Munson and Field, 1966
1968 Electrospray (ESI) for macromolecules Dole 1968
1974 Tandem quadrupole mass filter (QQQ) Vestal and Futrell, 1974
1975 Atmospheric pressure chemical ionization (APCI) Carroll et al., 1975
1979 Triple-quadrupole mass analyzer and selected ion
fragmentation
Yost and Enke, 1979
1984 ESI for small molecules and connection of LC to MS
via ESI
Yamashita and Fenn, 1984
1984 Quadrupole time-of-flight (QTOF) Glish and Goeringer, 1984
1988 CB1R found Devane et al., 1988
1988 Matrix-assisted laser desorption/ionization (MALDI) Karas and Hillenkamp, 1988
1989 Nobel Prize – Hans G. Dehmelt and Wolfgang Paul for
development of ion trap
The Official Web Site of the Nobel Prize,
Nobelprize.org
1992 CB1R cloned Matsuda et al., 1990
1992 AEA found to bind CB1R, first EC Devane et al., 1992
1993 CB2R cloned Munro et al., 1993
1993 LEA and DHEA found to bind CB1R Hanus et al., 1993
1995 2-AG found to bind CB1R and CB2R Mechoulam et al., 1995; Sugiura et al.,
1995
1996 Characterization of FAAH Cravatt et al., 1996
1999 AEA found to activate vanilloid receptors Zygmunt et al., 1999
2000 Atmospheric pressure photoionization (APPI) Robb et al., 2000
2001 2-AGE found Hanus et al., 2001
2002 Cloning and characterization of MAGL Dinh et al., 2002
2002 Virodhamine found Porter et al., 2002
2002 Nobel Prize – John B. Fenn and Koichi Tanaka for
development of soft desorption ionization methods
The Official Web Site of the Nobel Prize,
Nobelprize.org
2003 Cloning sn-1-DAG lipase Bisogno et al., 2003
2004 Molecular characterization of NAPE-PLD Okamoto et al., 2004
2004 Oleamide found to bind CB1R Leggett et al., 2004
2004 Desorption electrospray ionization (DESI) Takáts et al., 2004
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2.3 MASS SPECTROMETRY AND ENDOCANNABINOID METABOLISM
Several mass spectrometric methods have been published for the analyses of ECs and their
metabolism in biological samples (reviewed in Kingsley and Marnett, 2009; Zoerner et al.,
2011). Mass spectrometry (MS) is based on the production of ions, which are subsequently
separated according to their mass-to-charge (m/z) ratio, and finally detected. The tangible
product from the mass spectrometer is the mass spectrum, which plots the relative intensity
of  ions  as  a  function  of m/z. Mass spectrometers are highly sophisticated analytical
instruments that basically have five different aspects of operation; sample introduction,
ionization, mass filtering, ion detection, and a computer system to record and manage the
data. Mass spectrometry´s wide dynamic range, reproducibility in quantitative analysis, high
selectivity and sensitivity, ability to give information of molecular structures, and to analyze
biological samples with extreme molecular complexity make it, in concert with gas
chromatography (GC) or liquid chromatography (LC), the main analytical technology to
measure  ECs  in  biological  samples.  These  techniques  have  a  central  role  in  revealing  the
presence of ECs in both health and disease, in addition to situations of pharmacological or
dietary interventions (reviewed in Di Marzo, 2008).
ECs are highly hydrophobic and amphiphilic compounds that are present at pmol to nmol
per gram concentrations in biological samples. The extreme molecular complexity of the
sample matrix conspires to make the development and validation of analytical methods a
challenge for biological applications. Therefore, considerable disagreement in results
currently exists for ECs levels between different methods and instrumentation (e.g., GC-MS
vs.  LC-MS).  In  addition,  this  could  arise  from  a  wide  variety  of  other  reasons  including
variations in physiological and pathological stages, sample-dependent biological processes,
sampling, sample preparation, calibration, and instrumentation (reviewed in Kingsley and
Marnett, 2009).
2.3.1 Sample preparation and endocannabinoid metabolism
Despite the fast development in instrumental techniques, both sampling and sample
treatment remain the most crucial steps in the analysis of ECs in biological samples. ECs are
lipophilic compounds present at low concentration in biological material, and they are
sparingly  soluble  to  water  due  to  the  amide  and  glycerol  groups  attached  to  NAEs  and
MAGs, respectively. ECs are freely soluble to organic solvents over a wide range of polarity;
for example methanol, acetonitrile, toluene, ethyl acetate and combinations of solvents such
as methanol/chloroform (Hardison et al., 2006; Balvers et al., 2009; Zoerner et al., 2012).
ECs have been measured from a wide variety of biological materials. This analysis requires
two crucial sample preparation steps, which are common to all materials; that is, quenching
the enzymatic processes and extracting the ECs from the sample. These biological materials
include the cerebrospinal fluid (CSF) (Giuffrida et al., 2004), mammalian plasma (Giuffrida
and Piomelli, 1998; Obata et al., 2003; Giuffrida et al., 2000; Schreiber et al., 2007; Balvers et
al., 2009; Bilgin et al., 2015), mammalian tissues (Schmid et al., 1995; Stella et al., 1997;
Giuffrida et al., 1999; Yang et al. 1999; Schmid et al., 2000; Maccarrone et al., 2001; Hardison
et al., 2006; Patel et al., 2003; Bradshaw et al., 2006; Williams et al., 2007; Richardson et al.,
2007), brain microdialysates (Ferrer et al., 2007) and cell cultures (Fontana et al., 1995;
Maccarrone et al., 2001; Kingsley and Marnett, 2003).
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Sampling and quenching the enzymatic processes
Various physiological and pathophysiological states affect the EC system and cause notable
differences in ECs levels (Valenti et al., 2004; Bradshaw et al., 2006; Malinen et al., 2009; Patel
et al., 2004; Kirkham et al., 2002; Schmid et al., 1995; Kempe et al., 1996). Consequently, the
EC system has been linked to several neurodegerative diseases (Dean et al., 2001; Glass et al.,
1993; Maccarrone et al., 2011) and neuropsychiatric disorders (Vinod and Hungund, 2005;
Vinod et al., 2005). Also, some drugs have a measurable effect on the EC system (Giuffrida et
al., 1999; Ferrer et al., 2003; Giuffrida et al., 2004).
A strong post-mortem effect has been reported in analyses of ECs from biological samples
(Sugiura et al., 2001; Palkovits et al., 2008; Felder et al., 1996; Schmid et al., 1995; Kempe et
al.,  1996, Patel et al.,  2005).  The post-mortem effect is known to increase brain NAE levels
(Palkovits et al., 2008; Schmid et al., 1995; Kempe et al., 1996; Patel et al., 2005; Berger et al.,
2004). It has been demonstrated that NAEs’ post-mortem brain content accumulates as a
result of ischemia, membrane damage, excitotoxicity and increased intracellular calcium, all
of which cause the activation of the transacylation-phosphodiesterase pathway (Patel et al.,
2005; Berger et al., 2004). In addition, gradual degradation of FAAH enzymatic activity over
time in post-mortem brain may explain the progressive increase in AEA levels (Patel et al.,
2005; Berger et al., 2004; Palkovits et al., 2008). It has also been suggested that the
accumulation of AEA, but not PEA and OEA, is due to a nonenzymatic aminolysis process
of arachidonate-rich phospholipid or triglyceride by ethanolamine (Kempe et al., 1996; Patel
et  al.,  2005).  A  rapid  post-mortal  increase  in  2-AG  and  other  MAGs  in  rat  brain  after
decapitation has been reported, which may be related to a rapid breakdown of inositol
phospholipids and the subsequent generation of diacylglycerol, which can be further
metabolized to 2-AG by diacylglycerol lipase (Sugiura et al., 2001). An opposite post-mortem
effect on 2-AG has also been reported, where 2-AG in micro-dissected human brain rapidly
declined in a region-dependent manner (Palkovits et al., 2008). Similarly, a significant
increase in response to decapitation-caused ischemia has also been reported to free
ethanolamine, unesterified arachidonoyl acid and its metabolites levels (Miller et al., 1990;
Anton et al., 1983). The increase of free fatty acids could be up to 3,700% due to tissue thawing
and sample pretreatment phases (Jernerén et al., 2015). These findings show the importance
of post-mortem time interval of sampling and sample preparation.
Traditional techniques for quenching or stopping the enzymatic processes in biological
samples are the use of cold solvents (for example, methanol or acetonitrile), hot solvents (for
example, methanol or water), liquid nitrogen, acids (for example, perchloric acid) or bases
(Yanes et al., 2011). The advantages of these techniques are: efficient protein precipitation,
fast termination of cell metabolism, and a fast change in temperature for denaturing active
proteins. At the same time, the significant disadvantages are: the stability of metabolites
against high or low temperatures; the extreme pH values of quenching solution; and some
techniques are inadequate to precipitate proteins efficiently. In any case, these techniques are
unable to prevent decapitation-induced ischemia. This post-mortem effect could be avoided
by using heat stabilization, liquid nitrogen immersion or head-focused microwave fixation
(Farias et al., 2008; Jernerén et al., 2015). Microwave fixation has been used for quenching rat
brains,  and  basal  AEA  levels  were  reported  to  be  four  times  lower  in  samples  with
microwave radiation compared to decapitation (Bazinet et al., 2005).
Extraction of lipophilic metabolites
Quenching and extraction steps of sample preparation are often combined. The main goal is
to extract the sample in a way that is compatible with the instrument and technique used, so
that  the  sample  contains  as  much of  the  analyte  as  possible  (i.e.,  extraction efficiency and
recovery  are  high),  while  minimizing  the  amount  of  matrix  effect  causing  compounds.
Ultimately, the final objective is to stabilize and concentrate the analytes of interest for
eventual detection. Lipophilic metabolites are commonly extracted from biological material
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according to standard liquid extraction techniques (Folch et al., 1957; Bligh and Dyer, 1959).
Ethyl acetate, hexane and toluene have also been used for separating the lipid fraction from
a sample (Richardson et al., 2007; Kingsley and Marnett, 2003; Zoerner et al., 2012). The lipid
fraction of the extract contains phospholipids, which are also precursors to ECs. Therefore,
the artificial formation of ECs during the extraction step has to be monitored and taken in to
account  when  developing  sample  preparation  methods  for  ECs.  The  exposure  of  brain
extracts  to  either  base  or  acid  significantly  enhanced  the  appearance  of  AEA  (Yang  et  al.,
1999). In addition, acidification of the biological sample leads to the artificial formation of
lyso-PA by acid-catalyzed hydrolysis of more abundant lysophospholipids (Scherer et al.,
2009). Lyso-PA is produced through several enzymatic pathways but mostly from
lysophospholipids (Tigyi and Parrill, 2003; Aoki et al., 2008). It has also been reported that
both lyso-PC and PA are directly or indirectly converted to DAGs and then to MAGs (Sugiura
et al., 2001; Nakane et al., 2002). Base- and acid-catalyzed interconversion of NAEs from O-
acyl ethanolamines has been reported (Markey et al., 2000). Phospholipids are abundant in
biological membranes and PCs, as zwitterions provide one of the main sources for the matrix
effect  in  both  positive  and  negative  electrospray  (ESI)  MS  (for  example,  ion  suppression
and/or ion enhancement) (Piomelli et al., 2007; Little et al., 2006; Matuszewski et al., 2003;
Shen et al., 2005; Xia and Jemel, 2009). This matrix effect results from ionization competition
between the different species in ESI (King et al., 2000). The matrix effect is not reproducible
between tissue samples and thus could cause a systematic and/or random error in the results.
Therefore the matrix effect must be carefully investigated in the development of
methodologies, and it should be minimized by improved sample preparation,
chromatographic separation between both analytes and interfering matrix compounds, and
with consideration of the deuterated analogues as internal standards (Schuhmacher et al.,
2003; Matuszewski, 2006). Liquid-liquid extraction (LLE) was the most efficient extraction
procedure when compared with protein precipitation and common solid phase extraction
(SPE) techniques for removing potential matrix effects during sample preparation (Souverain
et al., 2004; Little et al., 2006). The superiority of toluene as an extraction solvent in plasma
samples, when compared to other commonly used solvents, has been reported (Zoerner et
al. 2012). Toluene extracted only 2 % of the phospholipids from plasma compared to
traditional solvent extraction methods (Folch et al., 1957; Bligh and Dyer 1959), which favors
LC-MS  based  methods  due  to  a  lower  matrix  effect.  The  use  of  toluene  as  an  extraction
solvent also shows no additional isomerization of 2-AG to 1-AG. In protic solvents, 2-AG
undergoes nonenzymatic acyl migration from sn-2 to the sn-1 position. This migration also
results  from  elevated  temperatures,  the  presence  of  serum  albumin  and  high  pH  values
(Schmid et al., 2000; Rouzer et al., 2002). In the analysis of ECs, extraction and the possible
evaporation of samples from polar or protic solvents was associated with a higher migration
of 2-AG to 1-arachidonylglycerol (1-AG) (Zoerner et al., 2012). Protein binding of AEA has
been reported to be high (> 99 %), which has to be considered during sample preparation and
in vitro studies (Bojesen et al., 2003; Oddi et al., 2008). In addition, adsorption of ECs to glass
and plastic surfaces has been reported (Giuffrida and Piomelli, 1998; Balvers et al., 2009; Oddi
et al., 2010).
In  many  methods  the  lipid  fraction  must  be  further  purified.  The  need  of  an  extra
purification step is related to the selectivity of the detection method (Schuhmacher et al.,
2003; Matuszewski, 2006). SPE with normal phase (Schmid et al., 1995; Fontana et al., 1995;
Stella et al., 1997; Schmid et al., 2000; Patel et al., 2003; Richardson et al., 2007) and reversed
phase (Kempe et al., 1996; Yang et al. 1999; Hardison et al., 2006; Bradshaw et al., 2006) have
been utilized for this purpose. The superiority of SPE reversed phase separation over normal
phase  in  the  purification  of  a  raw  lipid  extract  has  been  reported,  with  better  extraction
recovery and a lack of significant deuterium exchange with an isotopically labeled standard
of AEA (Hardison et al., 2006).
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Quality of the quantitative results
A quantitative mass spectrometric method for the analysis of ECs from complex biological
materials could be based on internal standard methods, external standard methods or
standard addition methods. The concentrations of analytes in the sample are usually
normalized by the weight of the sample (dry or wet material), protein or DNA concentration.
The development and validation of quantitative methods for the accurate and precise
determination of endogenous metabolites in biological samples is demanding. In addition,
the  high  lability,  high  polarity  range,  low  concentrations  of  analytes,  and  the  lack  of  an
analyte-free  surrogate  material  for  calibration  all  conspire  to  make  the  development  and
validation of analytical methods for targeted applications especially challenging. Therefore,
a considerable disagreement in analytical results of EC levels may exist between different
methods and instrumentation (for example, LC-MS vs. GC-MS). The objective of method
validation is to guarantee and document the quality of results with authentic analytes in an
authentic matrix (van de Marbel 2008). International guidelines have been published, to help
with documenting the validity of the bioanalytical methods (FDA, 2001; EMA 2009). These
guidelines cover the following parameters and tests: selectivity, calibration, accuracy,
precision, recovery, and stability. However, these guidelines have been prepared for drug
and drug metabolite analyses from biological samples, where the drug-free biological
surrogate material is freely available, and therefore some specific considerations must be
made when analyzing endogenous molecules from biological materials (van de Merbel,
2008). Due to the complexity of biological material and the possible matrix effect of this
material in the instrument (for example, ion suppression in ESI), the calibration standards
should be added to the analyte free biological surrogate material. ECs are endogenous
compounds that make finding an analyte-free surrogate material exceedingly difficult. Two
main strategies could be used to overcome this problem; that is, the use of an authentic
analyte in a surrogate material and the use of a surrogate analyte in the authentic material
(van de Merbel 2008). In addition, endogenous metabolites may be removed by a variety of
procedures, such as charcoal stripping, high-temperature incubation, acid or alkaline
hydrolysis, or affinity chromatography (Lee et al., 2006). Unfortunately these treatments
usually require extreme conditions that could cause artificial formation of the analyte(s) of
interest.  Authentic  analytes  can  be  analyzed  also  from  authentic  material  by  standard
addition  method,  which  eliminate  the  matrix  effect  (van  de  Marbel  2008).  In  standard
addition method increasing concentrations of the analyte is added to individual aliquots of
the sample, and the concentration is determinated from the intercept of the calibration curve
created from these aliquots. Unfortunately standard addition method requires more sample
volume and is more laborious than internal standard method, which prevent its use in large
sample sets. Furthermore, deuterated analyte analogues as internal standards may be added
to compensate for the loss of analyte during the sample preparation processes and for the
matrix  effect  on ionization.  These  internal  standards  are  added to  the  samples  at  an early
stage of sample preparation.
2.3.2 GC-MS analysis of endocannabinoid metabolism
Chromatographic separation
In gas chromatography (GC) the mobile phase is gas, which is usually helium or hydrogen.
The stationary phase  is  attached to  the  wall  of  a  long capillary  column.  The nature  of  the
stationary phase is typically that of a non-polar, highly viscous liquid in one-dimensional
chromatography, but it can also be polar in two-dimensional chromatography. In order to
analyze samples with GC, the samples have to be volatile, which mostly occurs in the heated
injector. Thus, one of the main limitations of this technique, is that molecules have to be small
non-polar molecules (< 1,000 Da) and they have to be thermally stable and volatile.  As an
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analytical  technique,  GC  is  not  suitable  for  the  analysis  of  EC  precursors,  such  as  high
molecular  mass  phospholipids.  Underivatized  ECs  have  been  analysed  by  GC-MS
(Maccarrone et al., 2001), but in most published GC-MS methods, derivatization has been
used to increase thermal stability and further improve the chromatographic and detection
properties of ECs and related compounds. NAEs and MAGs have been measured as their
silylated, acylated or halogenated derivatives with a splitless injection technique in non-polar
stationary phase capillary columns with MS detection (Schmid et al., 1995; Fontana et al.,
1995; Stella et al., 1997; Giuffrida and Piomelli, 1998; Giuffrida et al., 1999; Schmid et al., 2000;
Hardison et al., 2006; Kempe et al., 1996; Yang et al. 1999; Zoerner et al., 2009). The
simultaneous  measurement  of  ECs  and  other  eicosanoids  (e.g.,  prostaglandins  and
thromboxane) was accomplished after a multistep sample preparation and derivatization
scheme with diazomethane, O-hydroxymethylamine and dimethylisopropylsilyl imidazole
(Obata et al., 2003).
In quantitative analyses, the formation of an analyte´s derivative and the derivatization
reagents must follow the rules of stoichiometry that allow the chemical reaction to reach
completion. Another problem concerns the stability of a derivative, as Zoerner and co-
workers  (2009;  2012)  indicated  by  the  lack  of  stability  for  the  various  derivatives  of  2-AG
glycerol moieties and its migration product 1-AG. Together, with the above-mentioned
limitations, sample preparations related to GC techniques are considered to be laborious
when compared to LC-MS methods. Also the run time is considerably longer with GC than
modern ultra-high performance liquid chromatography (UHPLC) based methods, even
though the development for high-speed GC applications, with or without multidimensional
separation systems, has greatly decreased the analysis times and increased the separation
power of GC (Tranchida and Mondello, 2012).
Ionization
In the GC analyses of ECs, the most common ionization techniques are electron ionization
(EI), and chemical ionization in both positive (PCI) and negative (NCI) modes (reviewed in
Zoerner  et  al.,  2011).  EI  is  a  hard  ionization  method,  where  the  analyte  is  subjected  to
bombardment  by  energetic  electrons  (70  eV)  in  the  vapor  phase.  The  ionization  source  is
located inside the vacuum region of the mass spectrometry. The ionization generates a
radical cation (M+.)  called  the  molecular  ion,  which  has  an  excess  of  internal  energy.  This
energy excess causes a unique unimolecular dissociation reaction that results in fragment
ions that can be measured. These EI spectrums are highly reproducible,  which enables the
formation of large EI spectrum libraries. The other commonly used ionization technique in
GC is chemical ionization (CI), which is considered to be a soft ionization technique.
Ionization  techniques  can  be  defined  as  “hard”  or  “soft”  depending  on  the  extent  of
fragmentation that occurs during the ionization process. In CI, an additional reagent gas like
methane, isobutane or ammonia is introduced to produce reagent gas ions by electron
bombardment under a medium-pressure vacuum. These reagent gas ions react with analytes,
thus leading to ionization of the analyte molecules. These reactions include reagent/electron
reactions, proton transfer, charge exchange, electrophilic addition and anion abstraction in
the positive ionization mode, as well as proton transfer in the negative ionization mode. In
addition, this ionization technique enables the electron capture negative ionization, which is
a highly selective and sensitive ionization technique, especially for molecules containing
halogens. The power of EI and CI, in concert with the high resolution power of GC capillary
columns,  provides  a  highly  selective  and  sensitive  tool  for  the  analysis  of  ECs  present  in
biological materials.
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Mass analyzers and detection
The  simplest  and  most  widely  used  MS  detector  for  the  analysis  of  ECs  is  the  linear
quadrupole mass analyzer with electron ionization (EI) (Schmid et al., 1995; Fontana et al.,
1995; Stella et al., 1997; Giuffrida and Piomelli, 1998; Giuffrida et al., 1999; Schmid et al., 2000;
Maccarrone et al., 2001; reviewed in Zoerner et al., 2011). This analyzer separates ions based
on their m/z values, and on the stability of their trajectories in the oscillating electric fields
that are applied to the quadrupole rods (Paul, 1990). In single mass analyzer instruments,
two  different  data  acquisition  modes  can  be  used;  full-spectrum  analysis  (SCAN)  and
selected-ion  monitoring  (SIM).  SCAN  analysis  acquires  a  series  of  mass  spectra  and  it  is
typically applied in qualitative analyses. In SIM, preselected ions are monitored, which
substantially improves the signal-to-noise ratio. For this reason, SIM is used in the
quantitative analysis of ECs in biological materials (Maccarrone et al., 2001; Schmid et al.,
1995; Fontana et al., 1995; Stella et al., 1997; Giuffrida and Piomelli, 1998; Giuffrida et al., 1999;
Schmid et al., 2000). From hybrid MS analyzers, triple quadrupole (QQQ) instruments have
been used in combination with negative CI (NCI) for the analysis of NAEs (Zoerner et al.,
2009). In these analyzers, the first (Q1) and third (Q3) quadrupoles can be used as mass filters,
while non-mass resolving second quadrupole (Q2) is used as a collision cell to generate
fragments with an inert gas such as nitrogen or argon. This formation of fragments is called
collision-induced dissociation (CID). These hybrid analyzers provide additional analysis
modes; for example, product-ion scanning, precursor-ion scanning, neutral loss scanning,
and selected reaction monitoring (SRM), also known as multiple reaction monitoring (MRM).
Quantifier and qualifier ions are followed with SIM and MRM analysis for confirmation of
identity of analyte. In the quantitative analysis of biological samples, the power of selectivity
and ability to decrease the background noise with QQQ are highly appreciated. In addition
to quadrupoles, a high-resolution magnetic sector analyzer has been used to analyze silylated
N-arachidonoylserine (NArS) from bovine brain samples (Milman et al., 2006).
2.3.3 LC-MS analysis of endocannabinoid metabolism
Chromatographic separation
Liquid chromatography with mass spectrometric detection (LC-MS) can be used for the
direct analysis of a wide variety of compounds related to endocannabinoid metabolism,
without the need of hydrolysis or derivatization. ECs and molecules related to their
metabolism are mainly lipophilic and therefore a reversed phase (RP) separation technique,
together with a gradient mobile phase is widely used to separate ECs from the sample matrix
(Snyder et al., 2010; Bradshaw et al., 2006; Williams et al., 2007; Richardson et al., 2007;
Kingsley and Marnett, 2003; Schreiber et al., 2007; reviewed in Zoerner et al., 2011). ECs are
non-polar and highly hydrophobic compounds that are easily separated
chromatographically, and therefore separation does not require high buffer concentrations
in the LC methods. However, separation does require a significantly strong eluation media
(that is, a high portion of organic solvent in mobile phase) to completely pass through an RP
column. Normal phase separation has also been used in the analysis of AEA in rat brain and
peripheral tissues (Koga et al. 1997). In modern LC, column efficiency is mainly achieved by
decreasing the particle size of the packing with totally porous silica particles or superficially
porous particles in concert with different chemical moieties bound to the silica surface (for
example, C8, C18, phenyl, and cyano) (Snyder et al., 2010). Decreasing particle size has also
forced the development of a new generation of LC instrumentation that is capable of working
under back pressures near 1,000 bar (14,500 psi) (Nováková and Vlcková, 2009). 2-AG
undergoes nonenzymatic acyl migration from sn-2 to the sn-1 position in protic solvents,
resulting in a chromatographic peak that corresponds to 1-AG (Hardison et al., 2006). These
two  molecules  should  be  chromatographically  separated.  Typically,  in  the  case  of  2-AG
analysis, the peak areas of 1-AG and 2-AG were subsequently combined for all quantitative
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analyses  in  the  past,  and  collectively  termed  “2-AG”.  The  above-mentioned  new  UHPLC
column technologies and instrumentation provide an opportunity to analyze a growing
number of ECs, and the compounds involved in their metabolism, in a single measurement.
The increased column efficiency is also vital in separating isomeric and isobaric lipids.
Ionization
ECs and compounds related to  their  metabolism have been analyzed by LC-MS,  typically
with API techniques; that is, ESI (Giuffrida et al., 2000; Ferrer et al., 2003) and APCI (Koga et
al., 1997; Fezza et al., 2002; Patel et al., 2003; reviewed in Zoerner et al., 2011). These ionization
techniques are soft, and both are suitable for the direct analysis of thermolabile analytes. In
ESI the mobile phase is sprayed from the tip of the needle (nebulizer) at a high electrical
potential that is generated between the tip of the needle and the inlet of MS. In ESI the ions
are  formed  through  the  following  phases:  formation  of  a  conical  meniscus  known  as  the
Taylor cone; formation of a liquid jet; formation of varicose waves as a consequence of the
interaction between the viscosity and the surface tension on the surface of liquid jet;
formation  of  charged  droplets  from  the  mobile  phase;  droplets  with  shrinking  size  and
increasing charge density driving to increasing charge repulsion and exceeding the Rayleigh
limit; formation of new droplets by Coulombic fission; release of ions from microdroplets
into a gas phase by field desorption; and transport of formatted ions into the analyzer
(Gomez and Tang, 1994; Niessen, 2006). ESI is a concentration-sensitive process, and
therefore  increased  amounts  of  organic  solvent  and  decreased  flow  rate  are  known  to
strengthen the abundance of the followed ions. The ionization and transmission efficiency is
increased by employing ion source design, heat, gas flow, multi-bore capillary inlet and ion
funnels to improve the ESI process and the transfer of ions from atmospheric pressure into
the high vacuum region of the mass spectrometer (Kelly et al., 2010; Stahnke et al., 2012; Cox
et  al.,  2014).  These  new  source  designs  enable  higher  flow  rates  in  methods  that  use
electrospray ionization. ESI is known as the softest and most sensitive ionization technique
available for LC-MS in the analysis of moderate to high polarity analytes. In addition, it has
an  extended  mass  range  for  multiply  charged  analytes,  such  as  peptides  and  proteins.  A
complementary ionization technique to ESI is APCI, which is able to ionize less polar analytes
than ESI. APCI also has good sensitivity for analytes of intermediate molecular weight and
polarity. APCI is a chemical ionization process, where the mobile phase is nebulized to form
small droplets of vapor in the ion source, with heat and gas flow. The mobile phase molecules
are ionized by electrons from the corona discharge, a sharp needle with high voltage
positioned in the forming gas cloud. These reagent gas ions are formed from the mobile phase
and react with analytes, which leads to the ionization of analyte molecules. Like CI in GC-
MS instrumentation, these reactions include reagent/electron reaction, proton transfer,
charge exchange, electrophilic addition and anion abstraction in the positive ionization
mode, as well as proton transfer in the negative ionization mode. APCI is considered to be a
mass-flow sensitive ionization that allows for higher flow rates than ESI. In addition, APCI
is less sensitive to solution chemistry and matrix effects than ESI (Schuhmacher et al., 2003;
Matuszewski, 2006). The drawback of APCI is that analytes have to be thermally stable, and
they have to be partially volatile. With APCI, multiple charged ions cannot be formed, and
therefore the ionization technique is not compatible with larger biomolecules such as high
molecular weight peptides and proteins.
In analytical methods related to ECs, ESI has been shown to be slightly more sensitive than
APCI (Kingsley and Marlett, 2003; Williams et al., 2007). ECs were reported to have higher
peak areas in the positive ESI mode than in the negative mode (Giuffrida et al., 2000). AEA
generates higher intensity peaks than 2-AG due to the abundant protonation of the amide
group. ECs produce either the protonated molecule [M + H]+ or adducts with sodium [M +
Na]+ or potassium [M + K]+. Sodium and potassium adducts are highly resistant against CID,
and  are  not  recommended  as  precursor  ions  for  quantification  of  ECs.  Minimizing  the
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formation of Na+ and K+ adducts, using a mobile phase made from ammonium acetate and
avoiding contamination of any parts of the instrument are all highly recommended aspects
with LC-MS/MS techniques  (Zoerner  et  al.,  2012).  Silver  cation adducts  of  AEA and 2-AG
have been reported to have a very low limit of quantification (Kingsley and Marnett, 2003;
Schreiber et al., 2007). It should be noted, however, that certain mobile phase reagents; that
is, silver acetate, ammonium fluoride and ion pair reagents, may contaminate the instrument.
Mass analyzers and detection
The  most  widely  used  mass  analyzers  for  ECs  analyses,  by  LC-MS,  are  quadrupole  mass
filters, ion traps, and time-of-flight (TOF) analyzers (reviewed in Zoerner et al., 2011). These
all have high sensitivity, dynamic range and speed of spectra acquisition. In ion trap
analyzers three electrodes form a quadrupolar field, which traps the formed ions (Paul, 1990).
TOF  is  based  on  time  measurements  of  ions,  which  are  accelerated  by  an  electric  field  of
known strength. The velocity of the ions depends on the m/z ratio. Recent instrument
developments have enabled the use of high resolution mass analyzers, such as TOF, in the
quantitative analysis of biological samples (Ramanathan et al. 2011; Pelander et al., 2011).
Hybrid instruments, such as QQQ, quadrupole-ion trap (Q-TRAP) and quadrupole-time-of-
flight (QTOF) analyzers, have widened the identification power and selectivity for these
analyzers. In addition, combining these mass analyzers with API sources has recently given
these instruments an important role in the analysis of ECs and cannabimimetic compounds
(Bradshaw et al., 2006; Richardson et al., 2007; Williams et al, 2007). In addition, high mass
accuracy and high resolution QTOF detectors are widely used in non-targeted metabolite
profiling. In addition to increased ionization efficiency and ion transmission of new
instumentation, a new design of collision cells has improved also the speed and sensitivity
of the CID process,  in concert with reduced noise.  New data acquisition methods, such as
fast polarity switching and dynamic MRM (also termed scheduled MRM and timed MRM),
enables more molecules to be monitored in a single analytical run from a highly complex
biological sample. Polarity switching has been used to follow 43 different inflammatory and
pain-related lipid mediators; that is, eicosanoids, ECs and related bioactive lipids, in a rat
model of osteoarthritis (Wong et al., 2014). In addition, for library searches and identification
purposes  a  triggered MRM technique can be  used.  In  this  data  dependent  scan technique
MRM  is  combined  with  the  generation  of  a  product  ion  spectrum,  which  combine
quantitative analysis to qualitative identification, and therefore increase the selectivity and
throughput of an instrument.
2.3.4 Non-targeted metabolite profiling
The metabolome of an organism refers to the complete set of small-molecule metabolites that
are produced by cells. This includes endogenous molecules that occur as intermediates and
products of both catabolism and anabolism. As such, metabolites provide a functional
readout of the cellular state, and they provide insights into the biochemistries of disease,
toxicity, response to xenobiotic administration, in addition to the normal physiological
processes such as aging and the effects of nutrition (Patti et al., 2012; Reinke et al., 2010; Want
et al., 2013). In this context, non-targeted metabolite profiling, or metabolomics and
lipidomics,  has  become  a  powerful  analytical  tool.  There  are  two  general  approaches  to
metabolomics; targeted and non-targeted. In the targeted approach, only a defined set of
metabolites is measured. In non-targeted profiling, or global approach, as many metabolites
as possible are measured. The number and chemical composition of metabolites to be studied
is a defining attribute of any metabolomics experiment, and shapes the experimental design
with respect to sample preparation and choice of instrumentation (Patti et al., 2012; Want et
al., 2007). With developments in mass spectrometric instrumentation, and various software
solutions related to bioinformatics, it has become possible to measure thousands of
metabolites simultaneously from only minimal amounts of sample.
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In targeted metabolomics a specified list of metabolites is measured from a complex
biological specimen, within a wide polarity range of biomolecules. These measurements are
commonly driven by a specific hypothesis that is focused on one or more related metabolic
pathways of interest (Patti et al., 2012). This is possible due to the numerous publications that
have already described highly optimized protocols, the chemical composition of the
metabolites being investigated, in addition to the sample preparation and instrumental
analysis of specific metabolic classes (Astarita and Piomelli, 2009; Bajad et al., 2006; Dudley
et al., 2010). The most widely used instrument for targeted metabolite analysis is the QQQ
mass  spectrometer  in  combination  with  API  techniques  (that  is,  ESI  and  APCI),  high
performance liquid chromatography (HPLC), and more recently UHPLC (Nordström et al.,
2008; Patti, 2011; Want et al., 2007).
Non-targeted metabolite profiling aims to simultaneously measure as many metabolites
as possible from a biological specimen. These studies are often hypothesis generating, and
therefore it is important to carefully construct an experimental design that maximizes the
number of metabolites detected and their quantitative reproducibility (Patti et al., 2012). To
maximize  the  number  of  molecular  features,  it  is  possible  to  optimize  several  steps  in  the
non-targeted metabolite profiling workflow; that is, sample extraction, chromatographic
separation, ionization, mass filtering and detection of metabolites (Geier et al., 2011; Patti,
2011; Sandra et al., 2010; Yanes et al., 2011; Zhang et al., 2012; Want et al., 2007; Want et al.,
2013). Any artificial formation or degradation of metabolites should be avoided during
sampling, quenching and extraction. Most of the available extraction methods also produce
high sample dilutions, which should be avoided. Most frequently, data is collected with
UHPLC combined with high accuracy and resolution mass spectrometers with fast scanning
capabilities, like the QTOF mass spectrometer (Wikoff et al., 2009; Yanes et al., 2010). The
high resolution power (over  20,000)  and mass  accuracy (below 5  ppm) is  needed in  these
measurements. This enables the detection of thousands of molecular features from minimal
amount of sample, and therefore has been the technique of choice for non-targeted metabolite
profiling (Nordström et al., 2008; Want et al., 2007). In contrast to targeted metabolomics
results, non-targeted metabolomics data sets are exceedingly complex. Major progress has
been made in the past decade, so that the ability to measure unregulated peaks in a global
metabolomics data set has now become routine with the introduction of metabolomics
software solutions (Patti et al., 2012). After data acquisition, the results are processed by
bioinformatics software for peak picking, nonlinear retention time alignment, visualization,
relative quantification and statistical analysis (Patti et al., 2012). The m/z values for the peaks
of interest are searched from metabolite databases (for example, the Human Metabolome
Database (HMDB) and METLIN) to obtain tentative identifications, which are subsequently
confirmed by comparing tandem mass spectrometry (MS/MS) data and retention time data
with reference standards (Patti et al., 2012). The workflow of the non-targeted metabolite
profiling is presented in Figure 6, with a nematode (C. elegans) sample.
The metabolome is characterized by enormous chemical and structural diversities, where
metabolites can range from highly hydrophilic positively charged small molecules to
hydrophobic triglycerides and other large molecules. In addition, a significant challenge is in
the quantification over a wide concentration range of the metabolites present in the sample;
that  is,  ranging  from  millimolar  (mM,  10-3 mol/L) to attomolar (aM, 10-18 mol/L).
Consequently, many novel metabolites remain to be identified. Therefore, a major challenge
of non-targeted metabolomics still remains in effectively separating, forming ions and
detecting the chemically heterogeneous small molecules that comprise the metabolome.
Although a considerable amount of research has been directed towards this relatively new
area of non-targeted metabolite profiling, there is no uniform approach that is currently
available, and researchers must continue to use multiple complementary methods to
investigate the metabolome. Another drawback is that non-targeted profiling methods are
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unable to detect low concentration metabolites, such as most eicosanoids and for these
compounds targeted methods have to be developed and used.
Figure 6. The workflow of the non-targeted metabolite profiling. Abbrevations; HILIC, hydrophilic
interaction chromatography; RP, reversed phase; ESI(-), negative mode electrospray ionization;
and ESI(+), positive mode electrospray ionization.
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2.3.5 Nematodes and the endocannabinoid system
The nematode Caenorhabditis elegans (C. elegans) is a free-living, transparent, soil dwelling
worm and it is about 1 mm in length. It is widely used as a model organism in many areas of
biological research. In the 1960´s, Professor Sydney Brenner introduced C. elegans as a model
organism to the biological sciences for the investigation of animal development (Brenner,
1974). For discoveries related to genetic regulation of organ development and programmed
cell death, Prof. Brenner received the Nobel Prize in 2002, together with H. Robert Horvitz
and John E. Sulston (see The Official Web Site of the Nobel Prize, Nobelprize.org). As a model
organism, C. elegans are inexpensive and easy to maintain in a laboratory environment. Their
gross  anatomy  includes  a  mouth,  pharynx,  intestines,  gonads,  and  a  collagenous  cuticle
(Harris et al., 2014). Male and female hermaphrodites have 1,031 and 959 somatic cells,
respectively, of which 302 are nervous cells. Each synaptic connection and neuron lineage
has been mapped. These animals are mainly self-reproducing hermaphrodites, which can lay
over 300 eggs during their lifetime. The reproduction is primarily hermaphroditic,  but the
production of eggs could rise up to 1,000 if the hermaphrodite is inseminated by a male. The
development cycle is only a couple of days from egg to an adult worm, and the entire lifespan
is about two weeks. The development includes four different larval states before becoming a
reproductive adult, and dauer state, which is the alternative developmental state that occurs
as response to environmental stress, such as food restriction and/or overcrowding. C. elegans
was  the  first  animal  to  have  its  100Mb  genome  fully  sequenced,  and  over  20,000  protein-
coding genes mapped (The C. elegans Sequencing Consortium, 1998). Nowadays, a large
collection of mutants and a whole-genome RNA interference (RNAi) construct library are
available for these animals (Kamath et al., 2003; Harris et al., 2014). RNAi was first discovered
in C. elegans by  Professors  Andrew Z.  Fire  and Craig  C.  Mello,  and this  discovery earned
these  scientists  a  Nobel  Prize  in  2006  (see  The  Official  Web  Site  of  the  Nobel  Prize,
Nobelprize.org). The isolation of large quantities of genetically identical animals, or with
limited genetic variation, is easily possible with C. elegans. In addition to genetic factors,
environmental factors can also easily be controlled (Szewczyk et al., 2006).
Non-mammalian model organisms, such as, the yeast Saccharomyces cerevisiae, the fruitfly
Drosophila melanogaster, the zebrafish Danio rerio, and C. elegans, are well suited for modelling
the complex biological processes. C. elegans have orthologues for most of the key enzymes
found in the major metabolic pathways of eukaryotes (Braeckman et al., 2009). These animals
also  have  orthologues  to  533  known  human  disease  genes,  as  derived  from  the  Online
Mendelian Inheritance in Man database (Hariharan et al., 2003). C. elegans are widely used in
research related to reproduction, development, cell signaling, cell cycle, gene regulation,
metabolism and longevity (Lucanic et al., 2010; reviewed in Bishop and Guarente, 2007;
Hansen et al., 2013; Vrablik and Watts, 2013). C. elegans are able to biosynthesize all
polyunsaturated fatty acids (PUFAs) endogenously, and many processes of lipid biology are
conserved in this organism. Therefore these animals provide an exceptional model for the
study of lipid homeostasis and metabolism (reviewed in Ashrafi, 2007; Branicky et al., 2010;
Zhu and Han, 2014; Witting and Schmitt-Kopplin, 2015). The fat in this organism is stored in
lipid droplets, primarily in the intestine, which is considered as a multifunctional organ that
has  a  combined  role  of  liver  and  adipose  tissues  (Mak,  2012).  In  addition,  fat  storage
controlling pathways, that include insulin, transforming growth factor Ά (TGF-Ά), serotonin,
dopamine, glutamate and mammalian target for rapamysin (mTOR), are conserved (Ashrafi,
2007). C. elegans have also been used as a model to study non-cholesterol related branches of
the  mevalonate  pathway,  which  is  also  well  conserved  (reviewed  in  Rauthan  and  Pilon,
2011). C. elegans are a cholesterol auxotroph, meaning that they require cholesterol from the
diet. This model has also been used: for screening drugs, in the functional characterization of
drug  targets;  for  research  of  human  diseases,  such  as  Alzheimer´s,  Huntington´s,  and
Parkinson´s  diseases,  in  addition  to  cancer;  for  the  study  of  neural  and  neuromuscular
disorders; as well as to research metabolic disorders that lead to obesity and diabetes (Burns
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et al., 2010; reviewed in Kaletta and Hengartner, 2006). Behavioral studies have been made
in the context of addiction to alcohol and nicotine (Davies et al., 2003; Feng et al., 2006). These
animals can also serve as a genetic model for the study of host-pathogen interactions
(reviewed in Jones et al., 2005). Naturally, there are limitations in worms, in relation to the
study of human diseases. These animals do not have a blood circulatory system or lungs, for
example, and their response to different stress factors may be different than in humans. Of
the animal models, however, C. elegans is particularly advantageous in several respects, it has
a short development cycle, it is cost-efficient, and applicable to high-throughput
technologies. It may also provide answers in research on the early stages of drug discovery,
or in understanding the pathology of human diseases, by forming a bridge between in vitro
assays and mammalian models.
As a model organism, C. elegans is highly suitable for metabolomic studies. While small
molecules play important roles in the biology of C. elegans (Jeong et al., 2005; Gerisch et al.,
2007; Edmonds et al., 2010; Lucanic et al., 2011; Kosel et al., 2011; Vásquez et al., 2014;
reviewed in Branicky et al., 2010), surprisingly little research has focused on C. elegans as a
model organism in non-targeted metabolite profiling. Such studies rely on differing
instrumental technologies and multivariate analyses by sophisticated software solutions. To
date, the following non-targeted metabolite profiling studies in C. elegans have been carried
out: lipid profiling by “shotgun” lipidomics with Orbitrap MS, multiple precursor and
neutral loss scans with data dependent acquisition (DDA) (Schwudke et al., 2007); an effect
of nematode diet to metabolome by NMR (Reinke et al., 2010); an effect of sample preparation
to metabolome by NMR, GC-MS and LC-MS (Geier et al., 2011); a heat-shock perturbation to
metabolome  by  isotopic  ratio  outlier  analysis  (IROA)  and  Orbitrap  LC-MS  (Stupp  et  al.,
2013); a peroxisomal lipid Ά-oxidation by 2D NMR (Izrayelit et al., 2012); an aging related
changes to lifespan mutants metabolome by GC-EI-MS and GC-APCI-TOF-MS (Jaeger et al.,
2014) and also with LC-MS and nanostructure-initiator mass spectrometry (NIMS) (Patti et
al., 2014); and discovery of metabolic changes in Alzheimer disease by GC-MS and LC-MS
(Van Assche et al., 2015).
C. elegans produce ECs and other eicosanoids, that is prostaglandins and oxides (epoxy
and hydroxy derivatives) of both arachidonic and eicosapentaenoic acids (Vrablik and Watts,
2013). According to in silico studies, C. elegans seemed to lack enzymes for 2-AG biosynthesis
and degradation, as well as any functional cannabinoid receptor orthologues (McPartland et
al.,  2006B).  The  CeCO2H7.2  receptor  might  be  a  low  orthologue  of  CB1R,  but  it  may  not
function as a cannabinoid receptor (McPartland et al., 2006A). A radioligand study has
shown high-affinity binding for [3H]CP55,940 in the Panagrellus redivivus nematode, which
has been suggested as evidence for the presence of other non-CB1/CB2-type cannabinoid
receptors in nematodes (McPartland et al., 2006B; Elphick, 2012). The difference between
these two related nematodes may be due to the stream-lined genome of C. elegans (Copley et
al.,  2004).  These  nematodes  have  the  genes  encoding  for  homologs  of  FAAH  (faah-1;
B0218.1a), NAPE-PLD (NAPE-1; Y37E11AR.4) (McPartland et al., 2006A) and TRPV1 (osm-9)
(Tobin et al., 2002). In addition, orthologues of the human CRIP1a, a protein that is thought
to regulate CB1R signaling (Niehaus et al., 2007), has been found in C. elegans (Elphick, 2012).
A lack of functional cannabinoid receptors in C. elegans suggests that ECs may function as
signaling molecules in nematodes, particularly as ligands for other receptors, such as TRPV1
and/or PPAR΅ homologs (osm-9 and nhr-49, respectively), or as modulators of ion channels.
Lucanic and colleagues (2011) characterized the influence of ECs on mediating the effect
of diet on lifespan in nematodes. They also found, as in mammals, that the C. elegans NAPE-
PLD homolog NAPE-1 is not necessary for NAE synthesis, and that the FAAH orthologue
FAAH-1 has a role in degrading NAEs (Lucanic et al., 2011; Leung et al., 2006). A statistically
significant increase in AEA levels was found in a C. elegans mutant that lacked a functional
CYP-35A5 enzyme, which was suggested to be a homeostatic response to the decreased fat
content  of  these  animals  (Aarnio  et  al.,  2011).  The  CYP-35A  gene  family  has  a  role  in
27
regulation of different fatty acids and lipid stores in nematodes. In addition, AEA has been
identified  as  a  negative  regulator  of  axon  regeneration  (Pastuhov  et  al.,  2012).  Defective
peroxisomal lipid Ά-oxidation has also been reported to decrease the biosynthesis of ECs in
nematodes  (Izrayelit  et  al.,  2013).  This  study  linked  ECs  to  ascarosides  that  is  signaling
molecules of dauer formation, aging, and nematodes´social behavior (Jeong et al., 2005). In
aging,  OEA  was  suggested  to  promote  longevity  and  act  as  a  messenger  in  lysosome-to-
nucleus signaling (Folick et al., 2015). The C. elegans TRPV channels has been also linked to
insulin signaling (Lee and Ashrafi, 2008).
The EC system is complex and presents examples of convergent,  divergent and parallel
evolution. They may be considered as duplications and mutations of EC receptors to provide
new structures and functions (McPartland et al., 2006A). While our knowledge of this system
has developed and expanded during the last three decades, we still lack information to firmly
link processes at the synaptic level with those at the system level. C. elegans offers a unique
non-CB1/CB2-mediated  model  for  the  study  of  EC  signaling,  as C. elegans lack traditional
CB1R or CB2R, yet do encode a wide number of other GPCRs in addition to the TRPV1. These
examples  represent  different  processes  that  may  allow  this  animal  to  achieve  these  vital
physiological roles in other ways, and provide us with a new perspective in the consideration
of the EC system and its eventual evolution in mammals.
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3 Aims of the Study
The general objective of this study was to develop mass spectrometric methods for research
related to endocannabinoids. The main focus was to develop a highly selective and sensitive
quantitative method for research linked to the EC system in various biological materials. The
validation of a quantitative method was one important aim, due to the well documented fact
that specific difficulties occur in the analysis of ECs in biological samples (for example post-
mortem  effect,  stability,  calibration).  Another  aim  was  to  develop  a  high  accuracy  mass
spectrometric method for the non-targeted metabolite profiling of C. elegans, and to study the
utility of these nematodes as a biological model system in our research of the EC system.
The specific aims of the study were:
1. To verify the presence of ECs in C. elegans.
2. To  study  ECs  in  post-mortem  brains  of  Cloninger  type  1  and  2  alcoholics,  and  to
determine the possible correlations between dopamine and serotonin systems
through the EC profile of different alcoholic subtypes.
3. To study the validity of a quantitative mass spectrometric method for the analysis of
ECs from various biological materials, and further to study C. elegans fat-3 mutants as
a surrogate matrix for method validation of mass spectrometric applications related
to EC and eicosanoid research.
4. To study the effects of ethanol exposure and food deprivation on EC levels and the
global metabolome in C. elegans.
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4 Materials and Methods
4.1 INSTRUMENTS AND SUPPLIES
The analytical instruments,  columns and software used for the study are listed in Table 2.
The original publications are referred to by their Roman numerals. More detailed
information of materials and methods can be found in original publications I, II, III and IV.
Table 2. A list of instruments, columns and software
Instrument Manufacturer Publication
Mass spectrometry
Thermo Finnigan LTQ linear ion trap
MS (ESI)
Thermo Electron I
Agilent 6410 triple quadrupole MS
(ESI)
Agilent Technologies I, II, III, IV
Agilent 6540 QTOF-MS (JetStream
ESI)
Agilent Technologies IV
Agilent 5973N MSD (EI) Agilent Technologies II
Chromatography
Thermo Finnigan Surveyor HPLC Thermo Electron I
Agilent 1200 SL HPLC Agilent Technologies I, II, III, IV
Agilent 1290 UPLC Agilent Technologies IV
Agilent 6890 GC Agilent Technologies II
Software
XCalibur (Version 1.4) Thermo Electron I
Qual Browser (Version 1.4) Thermo Electron I
MassHunter Acquisition software
(version B.01.03 to B.04.00)
Agilent Technologies I, II, III, IV
MassHunter Quantitative Analysis
(Version B.01.03 to B.07.00)
Agilent Technologies I, II, III, IV
MassHunter Qualitative Analysis
(Version B.06.00)
Agilent Technologies IV
MassHunter Profinder B.06.00 Agilent Technologies IV
Mass Profiler Professional 12.6.1 Agilent Technologies IV
GraphPad Prism, version 5.03 GraphPad Software II, IV
SPSS for Windows, version 14.0 IBM SPSS software III
Columns
Zorbax Eclipse XDB-C18 RRHT (2.1
× 50 mm, 1.8 µm)
Agilent Technologies I, II, III, IV
Zorbax SB-C18 Rapid Resolution HT
2.1×50 mm, 1.8 µm
Agilent Technologies II
Zorbax Eclipse XDB-C8 2.1×50 mm,
3.5 µm
Agilent Technologies II
Zorbax Eclipse XDB-C18 1.0×150
mm, 3.5 µm
Agilent Technologies II
Zorbax Eclipse plus C18 3.0×100
mm, 3.5 µm
Agilent Technologies II
Zorbax Eclipse XDB-C8 (2.1 ×
100mm, 1.8 µm)
Agilent Technologies IV
Acquity  UPLC  BEH  Amide  (2.1  ×
100mm, 1.7 ǋm)
Waters IV
(Table continues to the following page)
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(Table continues from the previous page)
Instrument Manufacturer Publication
XBridge C18 2.5×50mm, 2.5 µm Waters II
Xterra MS C8 1.0×50 mm, 3.5 µm Waters II
General supplies
Water purification, Milli-Q Gradient Millipore I, II, III, IV
Analytical balance, AX205 Mettler-Toledo I, II, III, IV
Analytical microbalance, MT5 Mettler-Toledo II, III, IV
Nitrogen evaporator, N-EVAP 112 Organomation Assoc. I, II, III, IV
Homogenizer, Soniprep 150, MSE
Ultrasonic Disintegrator
MSE Scientific Instruments I, II, III, IV
Centrifuge, Eppendorf 5804R Eppendorf I, II, III, IV
Multilabel reader, Victor PerkinElmer I, II, IV
4.2 CHEMICALS AND CULTURES OF NEMATODES
The reagents and solvents used for the studies are listed in table 3. All solvents and chemicals
were  of  HPLC  grade  or  higher.  Water  was  purified  using  a  Milli-Q  Gradient  system
(Millipore, Milford, MA, USA). More detailed information of reagents and solvents can be
found in original publications I, II, III and IV.
Table 3. A list of reagents, solvents and nematode strains
Reagent / Solvents Manufacturer Publication
1-Oleoyl-2-hydroxy-sn-glycero-3-
phosphocholine (18:1 Lyso-2-PC)
Avanti Polar Lipids II
2-AG Cayman Chemicals I, II, III, IV
2-AG-d8 Cayman Chemicals I, II, III, IV
2-AGE Cayman Chemicals II
Acetonitrile J.T. Baker I
Albumin, Fatty acid free bovine
serum albumin (BSA)
Sigma
Ammonium formate Sigma IV
AEA Cayman Chemicals I, II, III, IV
AEA-d8 Cayman Chemicals I, II, III, IV
Chloroform Riedel-de Haën I, II, III, IV
LEA Cayman Chemicals II
DHEA Cayman Chemicals II
Formic acid Riedel-de Haën and Sigma I, II, III, IV
Methanol J.T. Baker and Sigma I, II, III, IV
NADA Cayman Chemicals II
O-arachidonoyl ethanolamine HCl
(virodhamine)
Cayman Chemicals II
OEA Cayman Chemicals II
PEA Cayman Chemicals II
Protein content, DC protein assay kit Bio-Rad I, II, IV
Nematode strains
C. briggsae reference wild type
(AF16)
Caenorhabditis Genetics Center (CGC) I
C. elegans reference wild type
(Bristol N2)
CGC I, II, IV
C. elegans natural isolate (TR403) CGC I
C. elegans fat-1 CGC II
C. elegans fat-3 CGC I, II
C. elegans fat-4 CGC II
CZ2485 (ahr-1 (ju145)) CGC IV
(Table continues to the following page)
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(Table continues from the previous page)
Reagent / Solvent Manufacturer Publication
RB1716 (nhr-49 (ok2165)) CGC IV
PR811 (osm-6 (p811)) CGC IV
CX10 (osm-9 (ky10)) CGC IV
Pelodera strongyloides Epp Moks, University of Tartu, Estonia I
Panagrellus redivivus Paul Sternberg, California Institute of
Technology, U.S.A.
4.3 SAMPLE PREPARATION
The sample preparation protocol for publications I, II, III and IV is  presented in figure 7.
More detailed information of sample preparation can be found in the original publications I,
II, III and IV.
Figure 7. Sample extraction protocol.
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5.Results and Discussion
The primary aim of this investigation was to develop mass spectrometric methods for
research related to ECs, and to study the utility of C. elegans as a biological model of the EC
system.  During  this  study  the  following  qualitative  techniques  were  used;  mass
spectrometric and genetic methods for the identification of ECs in C. elegans, in addition to
quantitative methods for analysis of ECs from various biological samples. Further, semi-
quantitative non-targeted metabolite profiling was used to study the effects of nutritional
stress on the global metabolome of C. elegans.  Results  from these  studies  are  divided into
three sections. In the first section (5.1), the identification power of the mass spectrometers to
reveal the identity of molecular structures is presented and discussed. The second section
(5.2) concerns the quantitative analysis of ECs, which includes method development and
validation, in addition to biological applications. Finally, the third section (5.3) presents non-
targeted metabolite profiling. The original publications are referred to herein by their Roman
numerals. More detailed information on these results can be found in publications I, II, III
and IV.
5.1 QUALITATIVE ANALYSIS OF ENDOCANNABINOIDS
In  qualitative  analysis,  the  main focus  is  to  identify  the  presence  and structure  of  a  target
compound. Therefore, selectivity of the analytical method is an extremely important
consideration in the analysis of a complex biological material. In this study the identification
power of three different mass spectrometers was used to identify ECs and related metabolites
in different nematode species (I)  and more specifically in C. elegans exposed to nutritional
stress, including starvation and ethanol exposure (IV). In concert with mass spectrometric
identification, C. elegans mutants verified the presence of the two main ECs, AEA and 2-AG,
in nematodes, and further confirmed the selectivity of our mass spectrometric methods (I
and II).
During these qualitative studies, we were able to reveal the presence of ECs in nematodes.
Aside from the novelty of this finding, this finding is also interesting because nematodes do
not seem to have cannabinoid receptors, yet C. elegans do have low to moderate homologies
with the known enzymes that metabolize ECs, namely MGL and FAAH. The natural
occurrence of ECs in nematodes not only expands the phylogenetic map for the presence of
ECs in animals, but also suggests the utility of nematodes as a model organism for research
of  the  EC  system.  This  finding  also  suggests  a  more  complex  system  than  previously
imagined for EC activity in eukaroytes.
5.1.1 Mass spectrometric identification of endocannabinoids
Two main ECs, AEA and 2-AG, were identified as endogenous products in three species of
nematodes (Caenorhabditis elegans, Caenorhabditis briggsae, and Pelodera strongyloides) (I). The
high identification power of three different mass spectrometers was used during these
studies,  including linear  ion trap (LTQ) and triple  quadrupole  (QQQ) instruments  for  the
qualitative analysis of ECs in nematodes (I) and quadrupole time-of-flight (QTOF) in the non-
targeted metabolite profiling of C. elegans (IV). AEA and 2-AG were identified in nematodes
by electrospray ionization ion trap MS/MS experiments operated in the positive ionization
mode,  together  with  a  sub  2  micrometre  reversed  phase  chromatographic  column  and
authentic reference standards. We used the sample preparation protocol presented in Figure
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7, which was based on a sample preparation protocol that was developed for our previous
study on ECs in alcoholic rats (Malinen et al., 2009). ECs were identified by identical product
ion scans and chromatographic retention times in biological samples, and compared to
authentic reference standards (I) (Figure 8).
Figure 8. Representative  base  peak  chromatograms  for  AEA  (A)  and  2-AG  (B),  with  positive
electrospray ionization product-ion spectra of [M+H]+ for AEA (C) and 2-AG (D) from wild type
(N2) C. elegans. Identification was based on identical retention time and product-ion spectra of
biological samples compared to authentic reference standards. The chromatographic peak of n-6
analogues of AEA (12.7 min) and 2-AG (20.9 min) are indicated with arrows.
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5.1.2 Biological identification of endocannabinoids
The presence  of  ECs in  nematodes  was further  explored with the  study of C. elegans fat-3
mutants (I) (Figure 9). These mutants lack ̇6 desaturase activity, and therefore these animals
fail to produce PUFAs with alkyl chain of twenty carbons, such as arachidonic acid (C20:4n6)
(Watts and Browse, 2002). The absence of C20 PUFAs in these mutants was confirmed with
GC-MS determination of total lipids expressed as fatty acid methyl esters (FAME) (Aarnio et
al., 2011). The representative chromatograms from wild type and the fat-3 mutant of C. elegans
are presented in Figure 9, which shows a clear absence of C20:4n6 in fat-3 mutant samples.
Subsequently, neither AEA nor 2-AG was detected in the fat-3 mutant of C. elegans (I and II)
by LC-MS. This further ensures the selectivity of mass spectrometric identification of AEA
and 2-AG in wild type nematodes.
Figure 9. Lack of C20 PUFAs was verified with GC-MS. The representative TIC chromatogram from
wild type (A) and fat-3 mutant (B) of C. elegans shows the absence of C20:4n6 in the mutant
strains. Arrows are used to highlight the specific retention time of C20:4n6 and the absence of
this PUFA in fat-3 mutants.
Wild type C. elegans are able to produce both n-3 (Ν-3) and n-6 (Ν-6) analogues of AEA
and 2-AG, which can be seen in LC-MS chromatograms as two separate peaks at each MRM
transitions, at m/z 348ĺ62 and m/z 379ĺ287 for AEA and 2-AG, respectively. Therefore, these
two analogues have to be chromatographically separated before detection. Figure 10 presents
the representative MRM chromatograms of AEA and 2-AG from C. elegans wild type N2, fat-
1 and fat-4 mutants, which were further used to verify the presence of ECs in nematodes and
the selectivity of the analytical method (II). Fat-1 and fat-4 mutants are unable to produce n-
3 and n-6 fatty acids, respectively.
The LC-MS method used in this portion of the study demonstrated high selectivity for the
analysis of 2-AG and AEA in nematodes and other biological materials.
C20:4n6
C20:4n6
C20:5n3
C20:4n3
C20:3n6
A B
C20:4n6
m/z 67.0
m/z 81.0
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Figure 10. Representative MRM chromatograms of AEA in C. elegans wild type N2 (A), fat-1 (B)
and fat-4 (C) mutants. Similarly, the presence of 2-AG is shown in C. elegans wild type N2 (D),
fat-1 (E) and fat-4 (F) mutants. Arrows indicate the specific retention times for the n-6 analogues
of  AEA (C)  and  2-AG (F).  The  chromatographic  peaks  of  n-6  analogues  of  AEA  and  2-AG are
indicated with darker shading.
5.2 QUANTITATIVE ANALYSIS OF ENDOCANNABINOIDS
The quantitative LC-MS/MS method was shown to be highly selective, linear, accurate, and
precise for the analysis of ECs in various biological materials. This method followed the four
main ECs, 2-AG, AEA, DHEA and LEA, as well as two other cannabimimetic compounds,
PEA and OEA, in human brains, rat brains and whole nematodes (C. elegans) (II). Single step,
liquid-liquid extraction ensured a high recovery of the studied molecules. In addition, the
stability of these molecules was demonstrated to be adequate for bio-analysis. The sub 2 µm
particle size column and ultra-high pressure instrumentation provided the possibility to
decrease the analysis time to 3.5 min for these ECs by increasing the mobile phase flow from
0.15 ml/min to 0.5 ml/min.
In quantitative analyses, the main goal is to assure the validity of any results obtained with
the selected method. Therefore, a considerable amount of work is used for the development
and optimization of sample preparation, the adjustment of various instrumentation
A D
C F
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parameters, and further validation of the method. The method development and validation
phases are discussed in sections 5.2.1 and 5.2.2, respectively. This quantitative LC-MS/MS
method was used to reveal statistical differences between EC levels in both alcoholics´ post-
mortem brains (III) and C. elegans after nutritional stress (IV). These biological applications
are discussed in section 5.2.3.
5.2.1 Method development
During method development, special attention was directed towards sample extraction and
to the chromatographic resolution between ECs as well as the ion suppression caused by
phospholipids (II). The sample preparation protocol and instrument parameters were
modified from our earlier studies,  including a study of the influence of ethanol on the EC
system in the brains of alcohol preferring AA rats (Malinen et al., 2009) and the development
of quantitative method for lysophosphatidic acids (lyso-PAs) in rat brains (Aaltonen et al.,
2010).
A brief homogenization of the sample with sonication in ice-cold methanol, and traditional
chloroform extraction of the lipid phase, was the most suitable sample preparation protocol
for most of the studied ECs. In addition, this extraction method mainly transfers lyso-PAs
from the lipid fraction to the water phase. The only exception was NADA, which most likely
needs an adjustment of pH to remain stable in a sample solution, as catecholamine structures
are  known to  be  more stable  at  low pH (Thorré  et  al.,  1997).  We also  studied the  effect  of
glassware with ECs, and found that the normal glassware used daily in our laboratory was
suitable for this method. The acyl migration of 2-AG was also followed. We found that the
use of ice-cold solvents, together with the avoidance of protic solvents, greatly minimizes
acyl migration. However, this migration did take place during long sample sequences, when
samples were stored in an auto-sampler for many hours. According to our quality control
(QC) samples, the migration influenced neither precision nor accuracy of the method.
Due  to  the  similarity  of  the  various  EC  molecular  structures,  we  used  an  isocratic  RP
method to separate these molecules. With the high resolving power of totally porous sub 2
µm silica particles and an isocratic mobile phase, we were able to detect an additional peak
in  the  MRM  channels  for  OEA  in  all  the  studied  biological  samples.  This  OEA  peak  had
previously been reported only with GC-MS/MS technique (Zoerner et al., 2009). We suggest
that this extra peak to be N-(cis-7-octadecenoyl)ethanolamine, which is a positional isomer of
OEA, where the double bond is in position nine (n-9). In addition, vaccenic acid methyl ester
(C18:1,  n-7) can be found in the GC-MS analysis of C. elegans. These two chromatographic
peaks in the MRM channel of OEA are not baseline separated, but as we focused our method
development on the quantification of AEA and 2-AG, we accepted this lack of resolution for
OEA. This isocratic method also resulted in a lack of back precipitation of the lipids at the
beginning of the chromatographic measurement. This phenomenon occurs when water is
added to the sample before injection, or the sample is injected to a mobile phase gradient that
has a high water content. Actually, the back precipitation of the lipophilic material from the
sample was seen during the last step of the sample preparation that is after water was added
to the evaporated chloroform residue, which was subsequently dissolved in acetonitrile. The
resulting precipitate was removed by centrifugation just prior to the sample injection.
Glycerophosphocholines (PCs) are known to be ion suppressing components in ESI, and
they are present at high concentrations in biological materials. These phospholipids should
be removed prior to analysis by specific extraction protocols, or the analytes of interest
should be chromatographically separated from PCs. Therefore, the chromatographic
separation between ECs and PCs was studied during the development of the
chromatographic method. We tested several RP columns and followed the separation
between ECs and PCs. In addition, AEA and virodhamide were found to have the same MRM
transitions, and therefore they had to be chromatographically separated. We used in source
fragmentation (IS-MRM) of PCs to study the retention of these lipids with two MRM
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transitions, which were m/z 104ĺ104 and m/z 184ĺ184. In this technique the high fragmentor
voltage  was  used  to  fragment  PCs,  Lyso-PCs  and  sphingomyelins  inside  the  ionization
source to produce ions m/z 104 and 184 (Little et al., 2006). For the final LC method, we chose
a short, narrow bore, high resolution, sub-2 µm RP column (Zorbax Eclipse XDB-C18 RRHT
2.1 × 50 mm, 1.8 µm; Agilent Technologies, Palo Alto, CA, USA).
PCs  are  also  known  to  be  strongly  retained  by  RP  columns.  We  witnessed  a  strong
interaction between PCs and the column stationary phase by following IS-MRM m/z 184ĺ184
of  blank  samples  injected  between  biological  samples  during  the  long  sample  sequence
(Figure  11).  For  this  part  of  the  study,  we  used  a  new  RP  column  with  nematodes  as  the
biological sample. Interestingly, we initially found the background signal (IS-MRM m/z
184ĺ184) to be close to zero, but this increased to an intense wave-like signal after only 50
injections. This background signal reached a maximum after 100 injections, and then started
to decrease when the shape of the signal began to stabilize. After 170 injections, this signal
reached a steady-state (Figure 11). PCs have been used as a coating of the stationary support
in  reversed  phase  chromatography  such  as  in  octadecylsilica  columns,  which  are  used  to
immobilized artificial membranes (IAM) (Krause et al., 1999). A PC coating can be bound by
either covalent or non-covalent bonds to the column´s stationary phase. Dynamic coating can
be  used  to  prepare  non-covalent  IAM,  where  PCs  are  energetically  favorable  when
distributed on the surface of the C18 phase by hydrophobic interaction and/or van der Waals
forces  between  the  acyl  groups  of  PCs  and  the  C18 phase  of  the  column  (Kamimori  and
Konishi, 2002; Luo et al., 2007). Partially because of this effect in our LC-MS method, we are
able to analyze thousands of biological samples without compromising the quality of the
results.  In addition, ECs did not suffer ion suppression by this steady state background of
PCs.
Figure 11. The dynamic coating phenomenon of PCs in the RP column. PCs were followed with the
IS-MRM technique; i.e., m/z 184ĺ184, with blanks samples injected between C. elegans samples
during a long sample sequence.
Injection number (#): 16, 49, 93, 149, 206
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5.2.2 Method validation
The validity of our LC-MS/MS method was demonstrated for the four most common ECs
analyzed in this study, 2-AG, AEA, LEA and DHEA, in addition to two other cannabimimetic
compounds,  PEA  and  OEA,  in  biological  samples  from  rats,  humans  and  nematodes  (II).
This method was found to be highly selective, linear, accurate, and precise for the analysis of
ECs derived from various biological materials.  In the case of PEA and OEA however, this
method could only be considered to be semi-quantitative. The validation results for two main
ECs, AEA and 2-AG, are presented in Table 4.
ECs are endogenous compounds and an analyte-free sample surrogate material was not
readily available for the validation studies. Therefore, we used the C. elegans fat-3 mutant as
an analyte-free surrogate material for both selectivity and calibration studies. The standard
addition  technique  was  used  to  study  both  selectivity  and  possible  matrix  effects  of  the
method. We found the method to be highly selective and free from matrix effects for all of
the  studied  ECs,  2-AG,  AEA,  LEA,  DHEA  and  OEA,  except  for  PEA.  According  to  these
results, our method underestimated the concentrations of PEA in the tissue by approximately
30%. In addition, we studied the issues of selectivity and analytical bias by sample dilution
and in-line infusion methods (Hartmann et al., 1998; Schuhmacher et al., 2003; Lee et al.,
2006). These studies ensured the lack of a matrix effect or signal interference, each of which
could cause an undetected systematic error in the results.
The calibration of the method was carefully evaluated by the use of standard addition and
the C. elegans fat-3 mutant. A concentration range of standards was chosen to cover the entire
concentration  range  of  each  of  the  ECs  present  in  the  biological  samples.  In  addition,  the
effects of curve fitting and weighing to the result´s quality were demonstrated. Calibration
curves, prepared over eight different concentration levels, were highly linear over the range
of the method for all of the studied ECs, including 2-AG, AEA, LEA, DHEA, PEA and OEA,
except in the case of NADA and noladin. The accuracy and precision of the method were
studied with QC samples that were prepared in a pure standard solution at four different
concentration levels, and in two different surrogate materials, bovine serum albumin (BSA)
and the C. elegans fat-3 mutant. The precision was further studied with rat brain homogenate.
The recovery was studied by using the standard addition method. Subsequently, the method
was demonstrated to be highly accurate and precise, together with high recovery values for
the studied ECs (that is 2-AG, AEA, LEA, DHEA, PEA and OEA). ECs were documented to
be chemically stable when stored frozen (Palkovits et al., 2008), hence the long-term stability
at -80°C of ECs in rat brain homogenates was subsequently tested and confirmed.
To our knowledge, this was the first report where the C. elegans fat-3 mutant was used as
a surrogate biological material for an analytical method development and validation. In our
laboratory, this mutant was successfully used during the selectivity and calibration studies.
Consequently, we proposed the C. elegans fat-3 mutant as a general surrogate material in
method development for the quantitative analyses of eicosanoids in biological samples.
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Table 4. The validation results for AEA and 2-AG with positive ESI LC-MS/MS
Validation parameter
AEA 2-AG
Calibration statistics
Linear range (nM) 0.2-62 38-11,321
The coefficient of determination (R2) 0.9992 0.9984
Slope of the curve ± 95 % CI 8.8096 ± 0.0195 4.4228 ± 0.0540
Intercept of the curve ± 95 % CI -0.0084 ± 0.0022 0.0055 ± 0.0951
Intra-day and inter-day (3 days) precision and accuracy statistics (n=5)*
Level LOD (0.4 nM AEA and 75 nM 2-AG)
- Accuracy (%)
- Precision (RSD%)
210 (n.d.)
1.7 (n.d.)
202 (n.d.)
2.6 (n.d.)
Level I (LLOQ) (1.0 nM AEA and 189 nM 2-AG)
- Accuracy (%)
- Precision (RSD%)
104 (101)
2.4 (4.1)
102 (98)
3.9 (5.7)
Level II (4.1 nM AEA and 755 nM 2-AG)
- Accuracy (%)
- Precision (RSD%)
102 (101)
2.2 (4.1)
104 (102)
1.3 (4.4)
Level III (21 nM AEA and 3774 nM 2-AG)
- Accuracy (%)
- Precision (RSD%)
101 (101)
1.2 (1.8)
100 (101)
2.4 (4.2)
Level IV (41 nM AEA and 7548 nM 2-AG)
- Accuracy (%)
- Precision (RSD%)
103 (102)
1.5 (1.5)
101 (100)
3.2 (2.7)
* the inter-day precision is presented in brackets next to intra-day values
5.2.3 Biological applications
C. elegans as a model organism for research in the endocannabinoid system
In an effort to better understand the pathology of ethanol administration and food
deprivation in animals, we investigated how ECs were affected in a wild type nematode, C.
elegans (N2) (IV). In addition, we studied the levels of ECs after food deprivation in nematode
strains  that  lack  receptors  linked  to  ECs,  including  in  CZ2485  (ahr-1(ju145)), PPAR΅
orthologue RB1716 (nhr-49 (ok2165)), PR811 (osm-6 (p811)), and vanilloid receptor orthologue
(osm-9 (ky10)).
The LC-MS method was able to quantify five ECs, 2-AG, AEA, LEA, PEA and OEA, in all
samples. We found that food deprivation significantly increased the levels of AEA and other
NAEs in all  the studied nematode strains. Food deprivation did not have any statistical effect
on the levels of 2-AG. The concentration of AEA´s and 2-AG´s n-3 analogue is higher than n-
6  analogue  in C. elegans. The nutritional stress of food deprivation and ethanol
administration, increased the concentration of AEA´s and 2-AG´s n-3 analogues more than
n-6 analogues. This effect was observed from the ratio value of AEA (or 2-AG) n-6 to n-3.
Interestingly, osm-9 mutants had no effect on this comparative value. Ethanol administration
cancelled the increasing effect of food deprivation on AEA and LEA, but not on PEA and
OEA. The levels of PEA and OEA were significantly increased after ethanol administration
in both fed and starved animals.  The levels of ECs after nutritional stress are presented in
Table 5.
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Table 5. The  effect  of  nutritional  stress,  that  is  food  deprivation  (starved)  and  alcohol
administration (EtOH), on ECs in different strains of C. elegans. The concentrations are presented
as  pmol/mg  of  protein  (± standard deviation).  Abbreviations:  N2,  wild  type C. elegans;  F,  fed
animal;  S,  starved animal;  F+EtOH, fed animal  after  ethanol  administration; S+EtOH, starved
animal after ethanol administration.
Strain 2-AG n-6 2-AG n-3 AEA n-6 AEA n-3 PEA OEA LEA
N2, F 501±228 1772±744 7.8±2.8 35±12 14±7 21±7 4.8±1.5
N2, S 492±275 2775±1451 25±8 208±80 29±9 40±9 9.3±2.6
N2, F+EtOH 259±83 940±213 4.5±0.8 24±5 7.4±1.8 13±4 3.7±0.6
N2, S+EtOH 241±76 2411±754 9.0±1.7 56±7 66±29 41±13 3.0±0.9
ahr-1, F 593±157 1015±263 29±9 52±14 10±4 19±7 8.0±2
ahr-1, S 797±429 1906±877 192±78 687±290 66±30 70±32 38±18
osm-6, F 261±78 833±185 3.9±0.9 16±4 6.3±1.8 8.9±3.8 2.4±0.5
osm-6, S 244±64 1371±340 64±17 327±88 29±5 32±6 15±3
nhr-49, F 795±440 1900±950 32±14 52±21 18±8 24±10 11±5
nhr-49, S 469±139 1931±606 117±29 504±128 46±11 46±11 26±7
osm-9, F 311±139 541±163 15±3 22±4 13±2 36±5 4.6±0.7
osm-9, S 463±130 792±142 85±32 130±58 35±14 96±31 12±4
We also studied the effect of nutritional stress to Panagrellus redivivus (P. redivivus). The
presence of other non-CB1/CB2-type cannabinoid receptor in P. redivivus has been suggested
(McPartland et al., 2006B; Elphick, 2012). We found that P. redivivus was unable to produce
high  levels  of  AEA  and  2-AG  n-3  analogues,  which  dominate  in C. elegans over  the  n-6
analogues. In addition, P. redivivus seemed to produce lower levels of AEA and higher levels
of 2-AG than C. elegans (Figure  12,  unpublished  data).  Interestingly,  it  seems  that  food
deprivation has no effect on these ECs in P. redivivus. Instead we found significant differences
(p=0.01, unpaired t-test with Welch´s correction) in OEA levels in P. redivivus after food
deprivation (Figure 12, unpublished data). OEA has been reported to regulate satiety and it
has a high affinity to PPAR-΅ (Fu et al., 2003).
Our results demonstrated a clear link between nutritional stress (feeding state and ethanol
exposure) and EC levels, which sheds additional light on the role of ECs as signaling
molecules in C. elegans.  After  the  discovery  of  ECs  in  nematodes  (I),  ECs  were  shown  to
mediate the effect of diet on the lifespan of C. elegans (Lucanic et al., 2011) and the control of
fat content in C. elegans mutants that lack a functional form of CYP-35A5 (Aarnio et al., 2011).
In addition, ECs have been linked to azon regeneration (Pastuhov et al., 2012), peroxisomal
lipid Ά-oxidation (Izrayelit et al., 2013), and lysosome-to-nucleus signaling (Folick et al.,
2015). Consequently, these results show nematodes to be a unique, non-CB1/CB2-mediated
model organism for the study of EC signaling in vivo.
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Figure 12. Effects of food deprivation on NAEs and 2-AG levels in wild type C. elegans (N2) and
P. redivivus.  A  statistically  significant  difference  in  ECs  was  observed  between  these  two
nematode species: AEA n-6 (A), AEA n-3 (B), ratio of n-6 to n-3 analogue of AEA (C); 2-AG n-6
(D), 2-AG n-3 (E), ratio of n-6 to n-3 analogue of 2-AG (F), PEA (G), OEA (H), and LEA (I). The
treatment of food deprivation is highlighted with darker shading. Data are the means ± SD of five
biological replicates per group. Data were analyzed by one-way ANOVA followed by a Dunnett´s
post hoc test. *p <0.05, **p<0.01, ***p<0.001 denotes significant difference compared to group
of N2 fed animals. The concentration axis is presented as logarithmic (log10) scale.
Post-mortem brain EC levels differ in Cloninger type 1 and 2 alcoholics when compared to controls
Alcoholics  form  a  heterogeneous  population  with  a  wide  spectrum  of  social  and  medical
problems. Alcoholics can be divided to two subtypes, according to the Cloninger model
(Cloninger, 1995). The  Cloninger  type  1  alcoholics  are  characterized  by  an  anxiety-prone
temperament and late onset of alcohol problems, that is “worriers”. By contrast, type 2
alcoholism (׽20% of alcoholics) is strongly influenced by heredity and is characterized by
teenage-onset heavy drinking and other forms of antisocial behavior. Type 2 alcoholics are
often  socially  hostile  young  men  who  tend  to  be  unusually  impulsive  risk  takers  that  are
prone towards violent behavior, that is “warriors”. We studied the EC levels in six different
post-mortem brain regions of Cloninger type 1 (n=9) and 2 (n=8) alcoholics, and compared
these results with those from a group of non-alcoholic controls (n=10) (III). The post-mortem
brain regions reported in III were  the  nucleus  accumbens  (NAC),  perigenual  anterior
cingulate cortex (pACC), frontal cortex and white matter.
Although  the  results  from  this  study  are  preliminary,  and  numbers  of  subjects  in  each
group were relatively small, our findings revealed statistically significant modifications in
brain EC levels for Cloninger type 1 and type 2 alcoholics. The LC-MS method was able to
quantify the four most common ECs, including 2-AG, AEA, LEA and DHEA, and two other
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cannabimimetic  compounds,  PEA and OEA,  in  the  NAC,  pACC,  frontal  cortex  and white
matter of all subjects. The  amounts  of  ECs  were  specific  to  both  brain  region  and  subject
group. 2-AG was the most abundant EC found in all studied brain regions. As a main result,
a  significant  difference  was  found  for  AEA  levels  in  the  NAC  between  the  three  groups
(p=0.047).  In  Cloninger  type  1  alcoholics,  AEA  levels  were  significantly  lower  when
compared to controls in both pACC (p=0.017) and frontal cortices (p=0.018). Similar trends
were observed for LEA and DHEA, but not for 2-AG, PEA or OEA. In the NAC, we found a
significant positive correlation between blood alcohol concentration and AEA in type 1
alcoholics, whereas in type 2 alcoholics, we found a significant negative correlation for AEA
and PEA with blood alcohol concentration. Post mortal interval negatively correlated only
with 2-AG in the NAC of type 1 alcoholics, but not in type 2 alcoholics or controls. In addition,
we found a significant correlation between NAC levels of AEA and densities of the vesicular
monoamine transporter 2 (VMAT2) in type 2 alcoholics (Spearman Ε=0.74, p=0.037). In type
1 alcoholics, we observed a significant positive correlation between D2/D3 receptor densities
and NAC levels of AEA (Ε=0.81, p=0.008), and a significant negative correlation between
D2/D3 receptor densities and NAC levels of 2-AG (Εƽƺ0.90, p=0.001).
A  major  challenge  for  reliable  EC  measurements  is  the  post-mortem  effect.  ECs  and
enzymes related to their synthesis and degradation are known to be brain-region related.
Interestingly, we found a statistically significant difference in the EC levels between white
matter and other studied brain regions, except for OEA. The levels of 2-AG and PEA were
statistically higher, while levels of other NAEs, including AEA, DHEA and LEA, were
statistically lower (Figure 13). These results seem to correlate with a study on post-mortem
changes of EC levels in human micro-dissected brains (Palkovits et al., 2008). Furthermore, if
these post-mortem change in EC levels are related to the region-dependent differences in the
distribution of EC degrading enzymes (Herkenham et al., 1991; Dinh et al., 2002; Hansson et
al., 2007). Consequently, it is tempting to suggest, that white matter EC levels could be used
as an in situ reference sample to either compensate for, or rule out, the post-mortem effect.
Clearly, well-controlled studies will be needed to fully evaluate these putative differences in
post-mortem effect between different brain regions.
Only a limited amount of data exists on human brain levels of ECs, and even less on their
putative function in alcoholics. According to our knowledge, this study is the first report to
investigate ECs in Cloninger type 1 and 2 alcoholics. Overall, these results suggest that brain
EC levels,  and mainly AEA, are increased in specific brain regions of the impulsive type 2
alcoholics.  In  contrast,  brain  AEA  levels  were  decreased  in  the  anxiety  prone  type  1
alcoholics, who also have attenuated dopaminergic transmission in the NAC reward system.
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Figure 13. ECs in white matter and other brain regions of human post-mortem brains. The study
control  group  was  non-alcoholic  (n=10).  Statistically  significant  differences  were  observed
between white matter and other brain regions for all ECs, 2-AG (A), AEA (B), DHEA (C), LEA (D),
and PEA (E), with the exception of OEA (F). Data presented are the means ± SD of ten biological
replicates. Data were analyzed by one-way ANOVA followed by a Dunnett´s post hoc test, where
*p<0.05, **p<0.01, ***p<0.001 denote significant differences compared to white matter
concentration. Abbreviations: AMY, amygdala; FC, frontal cortex; Hip, hippocampus; NAC,
nucleus accumbens; pACC, perigenual anterior cingulate cortex; W, white matter.
5.3 METABOLOMICS
In order to better understand the effect of nutritional stress, in the form of food deprivation
and ethanol administration, we built up and used a non-targeted metabolite profiling
method to provide insight into the cellular adaptation patterns of wild type C. elegans (IV).
The workflow and the sample preparation protocol for this non-targeted profiling of
nematode metabolites are presented in Figures 6 and 7, respectively.
The challenge in non-targeted metabolite profiling is to isolate and detect as many
metabolites as possible from a single sample, and to ensure the stability and identification of
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these molecules. Therefore, we decided to test our sample extraction method that was
developed for the quantitative analysis of ECs, for non-targeted metabolite profiling (Figure
7). In order to give the widest possible metabolome coverage for metabolites that might vary
during the development of each nematode strain, these sample populations were not
synchronized in this study and so, the samples analyzed consisted of a mixed population of
eggs, adults and various larval stages.
Due to the broad spectrum of physicochemical properties inherent in metabolites, we used
UHPLC and two different chromatographic separation mechanisms, RP and hydrophilic
interaction chromatography (HILIC), to cover a wide range of hydrophilic and
lipophilic/amphiphilic molecules. The coverage was further widened to detect additional
metabolites with both positive and negative ESI polarities, ESI+ and ESI-, respectively (Figure
14).  The  challenge  for  the  chromatographic  step  was  to  keep  retention  times,  signal
intensities, and mass accuracy values constant during the long sample sequence. Drift of the
signal and accumulated residue in the ion source could also compromise the quality of the
data during long sample sequences. In addition, ESI is known to have a strong matrix effect
that can prevent the accurate measurement of certain metabolites, such as hydrophilic
compounds  which  elute  close  to  the  void  volume  in  RP  techniques.  The  separation  and
detection of isomeric metabolites, that is stereoisomerism and regioisomerism, and isobaric
ions was also a challenge.
In the mass spectrometric detection of these samples, the aim was to maximize the
ionization efficiency of metabolites. The mobile phase had a strong influence on the
ionization  efficiency  (Kostiainen  and  Kauppila,  2009).  We  used  the  same  mobile  phase  in
both ionization polarities, even though the mobile phase containing ammonia or more
diluted solutions could improve the ionization efficiency in negative ionization (Zhang et al.,
2012). For a mobile phase, we used a water methanol mixture that contained 0.1 % (v/v)
formic acid for the RP technique, and a 20 mM ammonium formate buffer (pH 3) in a mixture
of acetonitrile and water with the HILIC technique. These mobile phases gave the most stable
signal, and with good peak symmetry, during the long sample sequences. In addition, one
identification criterion was the similarity of retention times, and therefore the same retention
time  between  two  different  polarities  was  a  benefit.  The  ion  source  design  also  improves
ionization efficiency, thus a heated ESI source was used in our method.
As a result, our four non-targeted profiling techniques revealed thousands of molecular
features from a typical nematode sample, for example from wild type C. elegans; 2030, 2630,
738,  and  1179  molecular  features  in  RP  ESI+,  RP  ESI-,  HILIC  ESI+,  and  HILIC  ESI-,
respectively  (Figure  14).  These  molecular  features  were  obtained by accurate  mass  with  a
computer software algorithm, which searches for the ion related isotopes, adducts,
multimers and fragments. Our extraction method was highly selective, since the chloroform
phase contained lipophilic and amphiphilic molecules, and the water-methanol phase
contained hydrophilic molecules. While some compounds were observed in both polarities,
many components ionized efficiently in only one of the two polarities, for example
triglycerides  were  visible  in  RP  ESI+  at  a  retention  time  range  between  12  to  16  minutes
(Figure 14 (A)), but not in RP ESI- (Figure 14 (B)).
We used a  batch molecular  feature  extraction software  (MassHunter  Profinder,  Agilent
Technologies), which is an untargeted feature extraction algorithm for aligning and binning
compounds from multiple data files by using neutral mass and retention time. Our data was
obtained from five replicates from each of the five sample groups, including from C. elegans
fed, C. elegans starved, C. elegans fed with ethanol administration, C. elegans starved with
ethanol administration, and quality control samples. We found molecular features extracted
from the above-mentioned samples containing significant amounts of noise, false negative
values, and signals with improper integration (Figure 15), which should be removed before
statistical analysis.
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Figure 14. Representative extracted compound chromatograms (ECC) from wild type C. elegans (N2) after RP-UHPLC-QTOF-MS in ESI+ (A) and in
ESI- (B). From the C. elegans chloroform extract,  RP separation provided positive and negative ionizations of  2030 and 2630 molecular  features,
respectively. HILIC separation was able to detect 738 and 1179 molecular features from the water-methanol phase of the extracted sample with ESI+
(C) and ESI- (D), respectively.
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Figure 15. Common  problems  with  non-targeted  metabolite  profiling  data  after  molecular  feature  extraction  (MFE),  included  noise  (A),  false
negative/positive values (B), and improper integration of signal (C). In this Figure, overlaid extracted ion chromatograms (EICs) are presented from
each study group, including C. elegans fed, C. elegans starved, C. elegans fed+EtOH, C. elegans starved+EtOH, and quality control (QC).
A B C
47
The first step of data processing was to remove noise from the original chromatographic
signals, and to import the resulting features into the Mass Profiler Professional 12.6.1
software (Agilent Technologies), which was used to further filter the data. In addition, this
software was used to create a list of consensus compounds. This list of compounds was used
to further process the data with Profinder software´s batch targeted molecular feature
extraction option. This option offers consistent peak integration and a missing feature
recovery option with a manual integration tool. These software and data treatments greatly
enhance  the  accuracy  and  robustness  of  the  molecular  feature  finding.  Consequently,  we
increased the quality of high accuracy mass spectrometric data before the application of
statistics, that is after the deletion of noise and false negative values. This data processing
had an additional significant impact on results from the statistical analysis, which can be seen
as  decreasing relative  standard deviation (RSD) values  within each of  the  sample  groups.
Table  6  presents  the  number  of  grouped  and  summarized  molecular  features  across  all
samples (n=25) after each data processing steps.
Table 6. Summary  of  results  for  the  number  of  grouped  and  summarized  molecular  features
across all samples (n=25) that were found by an untargeted feature finding algorithm. First the
data was extracted with Profinder software (Agilent), after MFE. Next, the recovered molecular
features were transferred to the Mass Profiler Pro software (Agilent) for STEP I, which was further
used to clean the data and to make a consensus list of compounds. This list was further used by
the Profinder software to extract consensus compounds from the data, to remove false negative
values, and to improve integration between samples (STEP II). Molecular features from STEP II
were transferred to the Mass Profiler Pro software for further statistical tests. Abbreviations: MFE,
molecular feature extraction.
RP ESI+ RP ESI- HILIC ESI+ HILIC ESI-
After MFE 5065 5529 2539 4491
STEP I* 3438 (40%) 3348 (40%) 2477 (40%) 2198 (40%)
STEP II** 2171 (100%) 2068 (100%) 900 (100%) 1503 (80%)
The numbers in parentheses denote the filter by frequency (Rel Freq.) value, which corresponds
to the number of features found in 40%, 80% or 100% of all biological replicates in at least one
condition.
*Abundance filter in step I was 2000
**Abundance filter in step II was 5000
Univariate and multivariate analyses were used for the statistical evaluation of the data.
One  way  analysis  of  variance  (ANOVA)  with  a  Benjamini-Hochberg  false  discovery  rate
(FDR) for multiple testing correction was used to find statistically significant features,
compared to wild type fed N2 nematodes. This test revealed 154, 732, 436 and 698 significant
(p<0.01) molecular features in RP ESI+, RP ESI-,  HILIC ESI+, and HILIC ESI-,  respectively.
Unsupervised principal component analysis (PCA) applied mean centering and scaling to
visualize  the  variance  and  clustering  of  the  metabolic  phenotypes  (Figure  16).  The  low
number of replicates (n=5) in each treatments can result in p-values of questionable statistical
validity,  and  therefore  the  data  was  further  explored  by  Volcano  plots,  in  which  the  fold
change (FC) of a molecular feature with normalized intensity was plotted against the
statistical significance of this change obtained with an unpaired t-test. The number of found
molecular features in Volcano plots are presented in Table 7.
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Figure 16. Unsupervised PCA score plot of significantly different molecular features found with a
one way ANOVA for RP ESI+ (A), RP ESI- (B), HILIC ESI+ (C) and HILIC ESI- (D). The cut-off p-
value in ANOVA was 0.01, and the Benjamini-Hochberg false discovery rate (FDR) was used to
correct multiple comparisons. Each point in the score plot represents a particular sample replicate
from four different study groups, including C. elegans N2 fed, starved, fed with ethanol (EtOH),
and starved with EtOH.
Table 7. The number of molecular features found with the Volcano plot in each instrumental mode.
In Volcano plots, the fold change (FC) of a molecular feature´s normalized intensity was plotted
against the statistical significance of this change obtained with an unpaired t-test. An unpaired t-
test and fold change (FC) were used with cut-off values for the FC with p-values of >2 and <0.01,
respectively.  The  Benjamini-Hochberg  false  discovery  rate  (FDR)  was  used  to  correct  multiple
comparisons.
RP ESI+ RP ESI- HILIC ESI+ HILIC ESI-
Starved vs. Fed 3 18 39 108
Fed+EtOH vs. Fed 40 9 29 119
Starved+EtOH vs. Fed 78 206 173 296
Identification of significantly differing metabolites between treatments were generated
according to accurate mass and isotope information, using ratios, abundances, and spacing,
as well as product ion (MS/MS) spectra by spectral matching from published databases
(including: Human Metabolome Database, Metlin, ChemSpider, LipidMaps, and SciFinder),
and earlier publications. When available, the fragmentation was verified with a commercial
standard. Data dependent product ion spectra were acquired at three collision energies, of
10, 20 and 40 eV (Figure 16).
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Figure 16. Representative extracted product ion (MS/MS) spectra for m/z 333.28 detected in ESI+
mode at three collision energies: 10 V (A), 20 V (B) and 40 V (C). The molecule was identified
with mass spectral information and the Metlin database as arachidonic acid ethyl ester (C22H36O2,
CAS 1808-26-0, Metlin number 404). The loss of an ethanol moiety [M+1-C2H5OH]+ can be seen
in the product ion spectrum with m/z 287.23, which corresponds to the arachidonoyl moiety.
Non-targeted metabolite profiling identified 107 significant effects between treatments.
The RP and HILIC techniques revealed 45 and 62 different metabolites, respectively. The RP
technique mainly identified fatty acid ethyl esters and phospholipids, while HILIC found 31
compounds linked to the metabolism of nitrogen. In addition, metabolites were from
divergent chemical classes, such as lipids and lipid-like molecules; nucleosides, nucleotides,
and their analogues; organic acids and derivatives; and organoheterocyclic compounds. The
biggest effect on the metabolome was observed in nematodes treated with food deprivation
together with ethanol administration. In Table 8 metabolites related to lipid and nitrogen
metabolisms are presented. These components were identified according to their accurate
mass and product ion spectrum, in tandem with a database and/or a pure reference standard.
C
B
A
m/z 46
m/z 287
m/z 46
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Table 8. Identified metabolites related to lipids and nitrogen metabolisms from all instrument
modes. The nutritional stress was studied with four different treatments; fed C. elegans, starved
C. elegans, fed with ethanol C. elegans, and starved with ethanol C. elegans. The effects show
up or down regulations on specific metabolites when compared to the control group, C. elegans
fed.
Annotation Molecular
formula
Retention
Time
Theoretical
mass
Mode Effect
Lipids and lipid-like molecules
2-Hydroxycaproate C6H12O3 0.71 132.0786 HILIC - Down
Mevalonic acid C6H12O4 1.85 148.0735 HILIC - Up
Acetylcarnitine C9H17NO4 3.09 203.1158 HILIC + Up
Trihydroxy-octadecenoic acid C18H34O5 3.37 330.2406 HILIC + Up
2-Hydroxyglutarate C5H8O5 4.60 148.0372 HILIC - Down
LysoPC (18:3) C26H48NO7P 6.31 517.3168 RP - Up
LysoPE (18:3) C23H42NO7P 6.37 475.2699 RP - Down
LysoPC (18:3) C26H48NO7P 6.51 517.3168 RP - Down
LysoPE (17:1) C22H44NO7P 6.99 465.2855 RP - Down
LysoPC (20:4) C28H50NO7P 6.99 543.3325 RP - Down
Į-Linolenoyl ethanolamine C20H35NO2 7.03 321.2668 RP + Down
LysoPC (17:1) C25H50NO7P 7.14 507.3325 RP - Down
LysoPE (20:3) C25H46NO7P 7.19 503.3012 RP - Down
LysoPC (20:3) C28H52NO7P 7.33 545.3481 RP - Down
Ǆ-Linolenic Acid C18H30O2 7.90 278.2246 RP - Down
O-hexanoyl-adenosine-
monophosphate
C16H24N5O8P 8.42 445.1362 RP - Down
Heptadecenoic acid C17H32O2 8.42 268.2402 RP - Down
Eicosadienoic acid C20H36O2 8.90 308.2715 RP - Up
Eicosapentaenoic acid ethyl ester C22H34O2 8.92 330.2559 RP + Up
Palmitic acid ethyl ester C18H36O2 8.93 284.2715 RP + Up
Ǆ-Linolenic acid ethyl ester C22H34O2 8.96 306.2559 RP + Up
Arachidonic acid ethyl ester C22H36O2 9.18 332.2715 RP + Up
Linoleic acid ethyl ester C20H36O2 9.28 308.2715 RP + Up
Dihomo-Ǆ-linolenic acid ethyl
ester
C22H38O2 9.49 334.2872 RP + Up
Oleic acid ethyl ester C20H38O2 9.60 310.2872 RP + Up
PC (20:5/18:4) C46H74NO8P 9.67 799.5152 RP - Down
PC (20:5/18:3) C46H76NO8P 9.85 801.5309 RP - Down
Nonadecenoic acid ethyl ester C21H40O2 9.88 324.3028 RP + Up
PC (20:5/15:1) C43H76NO8P 9.93 765.5309 RP - Down
PC (20:4/15:0) C43H78NO8P 10.04 767.5465 RP - Down
PC (18:3/16:0) C42H78NO8P 10.13 755.5465 RP - Down
PC (20:4/18:1) C46H82NO8P 10.27 807.5778 RP - Down
PC (20:4/19:1) C47H84NO8P 10.43 821.5935 RP - Down
PC (18:2/18:0) C44H84NO8P 10.56 785.5935 RP - Down
PC (20:3/19:1) C47H86NO8P 10.57 823.6091 RP - Down
(Table continues to the following page)
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(Table continues from the previous page)
Annotation Molecular
formula
Retention
Time
Theoretical
mass
Mode Effect
Metabolism of Nitrogen
Phenyllactic acid C9H10O3 0.75 166.0630 HILIC - Up
Methylthioadenosine C11H15N5O3S 0.76 297.0896 HILIC + Down
Phenethylamine glucuronide C14H19NO6 0.82 297.1212 HILIC - Down
Ketoisocaproate C6H10O3 0.87 130.0630 HILIC - Down
Glutaric acid C5H8O4 0.93 132.0423 HILIC - Down
Urocanic acid C6H6N2O2 1.17 138.0429 HILIC + Down
Adenine C5H5N5 1.18 135.0545 HILIC + Down
Hypoxanthine C5H4N4O 1.45 136.0385 HILIC - Up
Pseudouridine C9H12N2O6 1.53 244.0695 HILIC - Up
Methylhippuric acid C10H11NO3 1.56 193.0739 HILIC - Up
Uridine C9H12N2O6 1.56 244.0695 HILIC - Up
Xanthine C5H4N4O2 1.75 152.0334 HILIC - Down
Pyruvate C3H4O3 1.87 88.0160 HILIC - Up
Allantoin C4H6N4O3 1.97 158.0440 HILIC - Up
Inosine C10H12N4O5 2.62 268.0808 HILIC - Up
4-Guanidinobutanoic acid C5H11N3O2 3.92 145.0851 HILIC + Up
Tryptophan C11H12N2O2 4.05 204.0899 HILIC + Down
Guanidinosuccinic Acid C5H9N3O4 4.25 175.0593 HILIC + Down
Guanosine C10H13N5O5 4.28 283.0917 HILIC + Down
Uric acid C5H4N4O3 4.64 168.0283 HILIC - Down
Ǆ-Aminobutyric acid (GABA) C4H9NO2 4.69 103.0633 HILIC + Down
N2,N2-Dimethylguanosine C12H17N5O5 5.75 311.1230 HILIC + Up
Aminoadipic acid C6H11NO4 5.98 161.0688 HILIC - Down
Adenosine monophosphate C10H14N5O7P 6.48 347.0631 HILIC - Down
Uridine monophosphate C9H13N2O9P 6.56 324.0359 HILIC - Down
Histidine C6H9N3O2 6.68 155.0695 HILIC + Down
Guanosine monophosphate C10H14N5O8P 7.16 363.0580 HILIC + Down
Cystathionine C7H14N2O4S 7.54 222.0674 HILIC + Down
Phenylalanine C9H11NO2 2.21 165.0790 RP + Up
Collectively, these results demonstrate the power of non-targeted metabolite profiling to
study nutritional stress in C. elegans, and further complete a link between feeding states and
ethanol exposure on EC levels and the global metabolome. These animals have orthologues
for most of the key enzymes that are involved in the intermediary metabolism of other
eukaryotes, therefore making nematodes an especially convenient model to study energy
metabolism in vivo. As signaling molecules, ECs may mediate food restriction related
processes in C. elegans.
In addition, these results demonstrate the importance of accurate feature extraction in non-
targeted metabolite profiling, and the necessary removal of noise, false positive and negative
values, and signals with improper integration from the collected data. Such erroneous signals
have  a  significant  effect  on  subsequent  statistical  analyses,  and  therefore  they  must  be
removed or corrected. Further, in the era of non-targeted metabolite profiling, the targeted
quantitative methods are indispensable for analyzing the lowest concentrations of
metabolites that are present in the biological sample.
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6 Summary and Conclusions
In the present work, mass spectrometric methods were developed for research related to ECs,
and the utility of C. elegans as a biological model of the EC system was studied. The main
observations are summarized as follows:
1. A LC-MS/MS method for  quantitative  analysis  of  ECs was developed.  The method
followed  the  four  main  ECs,  2-AG,  AEA,  DHEA  and  LEA,  and  two  other
cannabimimetic  compounds,  PEA  and  OEA.  The  method,  based  on  sub  2  µm  RP
column separation and positive ESI triple quadrupole mass spectrometric detection,
was applied to several biological materials.  This same LC-MS/MS method has been
successfully applied to several other studies related to the EC system (Malinen et al.,
2009; Eckardt et al., 2009; Aarnio et al., 2011; Aaltonen et al., 2013; Muguruza et al.,
2013; Kärkkäinen et al., 2013; Aaltonen et al., 2014; Parkkari et al., 2014; Savinainen et
al., 2014; Navia-Paldanius et al., 2015).
2. A non-targeted metabolite profiling method for analysis of nutritional stress, in the
form of food deprivation and ethanol administration, in C. elegans was developed. This
method was based on UHPLC combined with heated ESI and QTOF. Two different
chromatographic separation mechanisms, RP and HILIC, were used to cover a wide
range of hydrophilic and lipophilic/amphiphilic metabolites. The coverage was
further widened to detect additional metabolites with both positive and negative ESI
polarities. As a result, this method was able to detect thousands of molecular features
from C. elegans.
3. We  were  the  first  laboratory  to  identify  and  quantify  ECs  in  three  species  of
nematodes, in C. elegans, C. briggsae and P. strongyloides. Our finding advocate the
utility of nematodes as a model organism for research of the EC system.
4. We revealed statistically significant alterations in the human post-mortem brain levels
of ECs for Cloninger type 1 and type 2 alcoholics. In addition, we demonstrated
significant correlation between ECs, AEA and 2-AG, and certain components of
dopaminergic and serotonergic neurotransmitter systems. These results suggest that
the EC system may be hyperactive in specific brain regions of the impulsive type 2
alcoholics, the “warriors”, and hypoactive in the anxiety prone type 1 alcoholics, the
“worriers”.
5. A quantitative LC-MS/MS method was validated. The method was shown to be highly
selective,  linear,  accurate  and  precise  for  the  analysis  of  ECs  in  several  biological
materials. Liquid-liquid extraction ensured a high recovery and the stability of these
molecules was adequate for bio-analysis. We were the first laboratory to use C. elegans
fat-3 mutants as a surrogate biological material for an analytical method validation.
Consequently, we propose the C. elegans fat-3 mutants as a general surrogate material
in analyses of eicosanoids in biological samples.
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6. The quantitative LC-MS/MS method and the non-targeted metabolite profiling
method revealed significant changes in levels of ECs and metabolite profiles in C.
elegans after nutritional stress. Food deprivation significantly increased the levels of
AEA and other NAEs, but not 2-AG, in wild type C. elegans and in nematode strains
that lack receptors linked to ECs. In addion, we found significant changes in certain
lipids and compounds related to the metabolism of nitrogen in wild type nematodes
after nutritional stress. These results demonstrate a clear link between feeding and
ethanol exposure on ECs and the global nematode metabolome, and shed additional
light on the role of ECs as signaling molecules in C. elegans. Consequently, C. elegans
offer a unique, non-CB1/CB2-mediated model organism for studies of EC signaling in
vivo, as these nematodes lacks both CB1R and CB2R, yet they do encode many other
GPCRs, in addition to the TRPV1. Nematodes can especially bring new information
on the physiological role of AEA, which has been shown to have fundamental
differences from 2-AG in the mode of EC signaling. Another exciting possibility is that
C. elegans and other nematodes may have functional cannabinoid receptors that have
not yet been discovered.
Future perspectives
The methods developed during these studies will be applied to the EC system related
research in our laboratory. Evidently, there is a need to further develop our LC-MS method
to study multiple signaling systems simultaneously. In addition, as localization of ECs is
crucial to their physiological function, techniques that would enable spatial analysis would
be advantageous and be beneficial for future studies. One possibility to study localization of
the  ECs  is  to  collect  small  samples  from  well-defined  anatomical  structures,  and  to  use
nanoscale instrumentation. Another method to analyze ECs in brain compartments could be
IMS that allows identification and quantitation of hundreds of metabolites on the cellular
level.
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